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 1.- Abbreviations 
 
15-LO  15- Lipoxygenase 
2-OG   2-oxoglutarate 
ABCA1  ATP-binding cassette transporter  A1 
ABCG1  ATP-binding cassette transporter  G1 
acLDL  acetylated-low density lipoprotein 
agLDL  aggregated-low density lipoprotein 
ALOX 15-B  arachidonate 15-lipoxygenase 
ApoE/B  apolipoprotein E/B 
ARNT  aryl hydrocarbon receptor nuclear translocator protein 
ATP   adenosine triphosphate 
BCLB  B-cell lymphoma 2 
bHLH  basic helix-loop-helix 
BNIP3  BCL2 adenovirus E1B 19 kDa protein interacting protein3 
CA IX  carbonic anhydrase 9 
CABG  coronary artery by pass surgery 
CBP   CREB1-binding protein 
CD   cluster of differentiation  
CE      cholesterol ester 
CETP  cholesteryl ester transfer protein 
CHIP   Hsp70-interacting protein 
CoA   coenzym A 
CS-1   connecting segment 1 
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CXCL16  chemokine (C-X-C motif) ligand 16 
DMOG  dimethyloxaloylglycin 
EGF   epidermal growth factor 
EGLN3  egl nine homolog 3 
EPAS1  endothelial PAS domain-containing protein 1 
ER   endoplasmic reticulum 
FA   fatty acid 
FACS  fluorescence activated cell scanning 
FC   free cholesterol 
FEEL-1  fasciclin, EGF-like, laminin-type EGF- like, and link  
FIH   factor inhibiting HIF-1 
FM   fluorescence microscopy 
GLUT-1/3  glucose transporter 1/3 
HAF   hypoxia-associated factor 
HDL   high density lipoproteins 
HIF   hypoxia-inducible factor 
HRE   hypoxia response element 
HSP-70  70 kilodalton heat shock protein 
ICAM  intercellular dhesion molecule 1 
IFN-γ   interferon gamma 
IΚ-β   inhibitor of NFκβ  
ΙΚΚ−β  Iκβ kinase  
IL   interleukin  
iNOS   inducible nitric oxide synthase 
LCAT  lecithin-cholesterol acyltransferase 
5
LDHA  lactate dehydrogenase A 
LDL   low density lipoprotein 
LIMP II  lysosomal membrane protein 2 
Lox-1  lectin-like oxLDL receptor 1 
LRP   low density lipoprotein receptor-related protein 1 
LXR   liver x receptor 
MARCO  macrophage receptor with collagenous structure 
MCP-1  monocyte chemoattractant protein-1 
MCSF  macrophage colony stimulating factor 
MCT 4  monocarboxylate transporter 4 
MHC   major histocompatibility complex 
MIF   migration inhibitory factor  
mmLDL  minimally modified LDL 
MMP   matrix metalloproteinase 
NFκB   nuclear factor kappa of activated B-cells 
OCT   octamer binding transcription factor  
ODD   oxygen-dependent degradation  
OLR1  oxidized low-density lipoprotein receptor 1 
ORO   oil red O 
ORP 150  150 kDa oxygen-regulated protein 
oxLDL  oxidized low density lipoprotein 
p300/CREB p300  cAMP response element-binding protein 
PAS   Per-ARNT-Sim 
PDGF  platelet derived growth factor 
PFK   phosphofructokinase 
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PHD   prolyl hydroxylase domain-containing protein 
PPAR  peroxisome proliferator-activated receptors 
RACK 1  receptor for activated protein kinase C 1 
ROS   reactive oxygen species 
SCAP  SREBP cleavage-activating protein 
SCARA5  class-A scavenger receptor 5 
SIRT-1  sirtuin-1 
SRA   scavenger receptor A 
SRB   scavenger receptor B 
SRC 1  steroid receptor coactivator 1 
SRCL  scavenger receptor with a C-type lectin domain 
SREBP  sterol regulatory element binding protein 
SREC  scavenger receptors expressed by endothelial cells 
SR-PSOX   SR-PSOX/CXC chemokine ligand 16 (CXCL16) 
C-TAD  C-terminal transactivation domain 
N-TAD  N-terminal transactivation domain 
TNF-α  tumor necrosis factor-alpha 
VCAM-1  vascular cell adhesion molecule 1 
VEGF   vascular endothelial growth factor  
VHL   von Hippel - Lindau 
VLDL  very low density lipoprotein 
VSMC  vascular smooth muscle cell 
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2. Zusammenfassung 
Arteriosklerotische Plaques im fortgeschrittenen Stadium bilden einen hypoxischen Kern 
aus, aufgrund der sich verdickenden Arterienwand und der daraus resultierenden 
verminderten Sauerstoffdiffusion. Cholesterinhaltige Makrophagen (schaumzellen) 
spielen eine Schlüsselrolle in der Ausbildung dieser Plaques, denn sie exprimieren sog. 
„Scavenger Rezeptoren“, die an der Aufnahme von Lipiden beteiligt sind. Die 
unterschiedlichen Expressionsmuster dieser Rezeptoren unter hypoxischen 
Bedingungen müssen jedoch noch untersucht werden. Mit Hilfe von qPCR, Zytometrie 
und Proteinanalyse mittels Western Blot fanden wir erhöhte mRNA und 
Proteinexpressionslevel des „Scavenger Rezeptors A“ (SRA) und des „Clusters of 
Differentitation 36“ (CD36) unter Zugabe des oxidierten Lipoproteins niedriger Dichte 
(oxLDL). Jedoch waren die Expressionslevel beider Rezeptoren vermindert, wenn 
Makrophagen Hypoxie ausgesetzt wurden. Im Gegensatz dazu war der mRNA und 
Proteinexpressionspegel des „ Scavenger Receptors Lektin-Like oxLDL“ (Lox-1) in 
Hypoxie erhöht. Mit Hilfe der Zytometrie konnte der erhöhte intrazelluläre Lipidgehalt in 
hypoxischen Makrophagen bestätigt werden. Des Weiteren konnte mit Hilfe einer 
Blockade des Lox-1 Rezeptors ein reduzierter Lidpidgehalt und eine verminderte 
Aufnahme von oxidierten LDL in Makrophagen beobachtet werden. 
Immunohistochemische Analysen menschlicher Koronarplaques zeigten eine Reduktion 
des SRA und des CD36 Rezeptors entlang eines Gradienten von der Adventitia zur 
Intimia hin, während Lox-1 hauptsächlich im hypoxischen Kern des Plaques 
nachweisbar war. Die Expressionsreduktion des Hypoxie induzierbaren Faktors 1α (HIF-
1α) unter Verwendung der siRNA und shRNA Methode änderte die Expressionspegel 
der SRA und Lox-1 Rezeptoren in hypoxischen Makrophagen. Diese Ergebnisse 
demonstrieren, dass Hypoxie die Expression der oxLDL Rezeptoren  unterschiedlich 
reguliert und dass Lox-1 die Hauptrolle bei der Hypoxieabhängigen Bildung von 
cholesterinhaltigen Makrophagen spielt.  
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3. Summary 
 
Advanced atherosclerotic plaques become hypoxic in their core as the arterial wall 
thickens and oxygen diffusion capacity is impaired. Macrophage-derived foam cells in 
atherosclerotic lesions play a pivotal role in plaque formation by expressing 
scavenger receptors that are involved in lipid uptake. Their differential expression in 
the context of hypoxia remains to be determined. Using qPCR, flow cytometry and 
Western blotting approaches, we found that mRNA and protein expression levels of 
the scavenger receptor A (SRA) and the cluster of differentiation 36 (CD36) were 
upregulated by oxidized low-density lipoprotein (oxLDL), but decreased following 
exposure of macrophages to hypoxia. In contrast, scavenger receptor lectin-like 
oxLDL 1 (Lox-1) mRNA and protein levels were upregulated under hypoxic 
conditions. Flow cytometry confirmed the increased lipid content in macrophages 
after exposure to 0.2%  oxygen (hypoxia). Furthermore, blockage of Lox-1 decreased 
the hypoxic induction of lipid content and oxLDL uptake in macrophages. 
Immunohistochemistry of human coronary plaques showed a gradual decrease of 
SRA and CD36 from the adventitia to the intima, while Lox-1 was mainly found in the 
inner core of the plaque, where an increased tissue hypoxia is present. shRNA or 
RNAi mediated knock-down of hypoxia-inducible factor (HIF)-1α in macrophages 
altered the expression of SRA and Lox-1 receptors in hypoxia. Our results 
demonstrate that hypoxia differentially regulates the expression of the three oxLDL 
receptors and that Lox-1 plays a major role in hypoxia-induced foam cell formation. 
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4. Introduction 
 
4.1 Atherosclerosis 
 
Atherosclerosis, the main cause of myocardial infarction and stroke, is a chronic 
and progressive inflammatory disease. It refers to the development of an atheroma 
plaque in the inner lining of the arteries, a normally small area between the endothelium 
and the underlying smooth muscle cells of the media, and results from the interaction 
between modified low-density lipoproteins (LDL), activated endothelial cells, monocyte-
derived macrophages, T-cells, and the vessel wall [1].  
 
Diverse genetic and environmental risk factors have been identified by 
epidemiological studies, such as hypertension, diabetes, insulin resistance, obesity, 
environmental factors, smoking, lack of exercise, high fat diet, amongst others.  But the 
elevated levels of serum cholesterol are probably unique in being sufficient to drive the 
development of atherosclerosis in humans and experimental animals, even when other 
known risk factors are absent. The investigation of molecular mechanisms that control 
cholesterol biosynthesis and serum cholesterol levels led to the development of statins 
[2], a potent class of cholesterol lowering drugs that reduce cardiovascular mortality in 
hypercholesterolemic patients. However, available statins are not sufficient to fully 
prevent the progression of the disease in susceptible individuals. 
 
An atherosclerotic lesion starts in the form of a fatty streak underlying the 
endothelium of large arteries. The principal cellular events that contribute to its formation 
are the recruitment of macrophages and its subsequent uptake of LDL. Several lines of 
evidence have already shown that modifications in the lipid component and the 
apolipoprotein B (apoB) parts of LDL drive the initial steps in the formation of a fatty 
streak [3]. 
 
The stability of atherosclerotic plaques is given by the extracellular matrix and a 
thick fibrous cap. An unstable plaque has a thin fibrous cap and thrombus at the 
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shoulder, it includes many inflammatory cells and a large lipid core. The plaque ruptures 
when the fibrous cap breaks and the necrotic lipid core (which is very thrombogenic) is 
exposed to the blood in the arterial lumen. The margins of the plaque contain 
macrophages, T lymphocytes and a paucity of smooth muscle cells. Fissures and 
plaque rupture are the cause for the great majority of thrombi that lead to acute coronary 
syndromes [4]. Figure 1 depicts the evolution of atherogenesis, from an initial stage up 
to the ruptured plaque and formation of a thrombus. 
 
 
Fig. 1 Progression of an atherosclerotic lesion: from a fatty streak to the ruptured 
plaque (from [5]). 
 
Infiltration of macrophages into the subendothelial space is a key step in early 
atherogenesis. Eventually, these inflammatory macrophages ingest oxLDL via 
scavenger receptors and become foam cells, thereby promoting plaque formation.  
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4.1.1. Initiating events: LDL modification and monocyte/macrophage 
recruitment 
 
Under normal conditions LDL is protected from oxidation in the plasma 
compartment, but when retained by extracellular matrix proteins in the artery wall, it 
gets susceptible to enzymatic and non-enzymatic modifications. Studies tried to 
understand potential oxidant-generating systems that could directly or indirectly target 
LDL. Some of them include mielo peroxidase, NADPH oxidase, nitric oxide synthase 
and 15-lipoxygenase (15-LO) [3]. 
 
In spite that monocyte and macrophage recruitment to the arterial wall can 
have an initial protective function, it can ultimately lead to the development of the 
atherosclerotic lesion [6]. Macrophages initially remove cytotoxic and proinflammatory 
oxLDL particles or apoptotic cells, but progressive accumulation of macrophages and 
their accumulative uptake of oxLDL make them become a foam cell, which is a 
hallmark for the progression of the disease.  
 
As mentioned above, LDL is exposed to oxidative modifications in the 
subendothelial space, progressing from minimally modified LDL (mmLDL), to 
extensively oxidized LDL (oxLDL). Circulating monocytes attach to the endothelial 
layer of cells that have been induced to express cell adhesion molecules. Once 
attached to the endothelial cell, monocytes enter the intima by diapedesis between 
the endothelial cells and their junctions. Families of chemoattractant cytokines 
(chemokines) have been defined as capable of recruiting macrophages into the 
arterial intima. It has been shown that, for example, overexpression of monocyte 
chemoattractant protein-1 (MCP-1) can recruit monocytes that characteristically 
accumulate in the early lesion.  IL-8, IFN-γ and other chemokines may have similar 
function as MCP-1 during atherogenesis [6]. 
 
The recruitment of monocytes to the sites that are more prone to develop an 
atherosclerotic lesion in the arteries, is regulated by cell adhesion molecules that are 
expressed on the surface of endothelial cells in response to inflammation.  Several 
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cell adhesion molecules have been identified to play roles in macrophage recruitment. 
One of the first to be implicated was VCAM-1, based on its increased expression on 
endothelial cells over lesion-prone areas [7]. Furthermore, E selectin and P selectin 
play significant roles in monocyte entry based on a 40% to 60% decrease in 
atherosclerosis in apo E–deficient mice that lack genes which codify for both selectins 
[8].  Moreover, gene deletion of ICAM-1 resulted in the reduction of monocyte 
recruitment to atherosclerotic lesions in apo E–deficient mice [9] . Another study with 
a peptidomimetic that corresponds to the connecting segment 1 (CS-1) domain of 
fibrinectin 1 (which blocks the function of  adhesion molecule VLA-4 on the leukocyte 
surface) decreased lipid accumulation in C57BL/6J mice fed an atherogenic diet [10]. 
Taking together, these findings suggest that there are many cell adhesion molecules 
involved in the recruitment of monocytes and T cells to the atherosclerotic lesion. 
Neutrophils, which normally contribute to most inflammatory responses, are 
interestingly absent in lesions, and the mechanisms leading to their absence remain 
to be defined. Figure 2 depicts the initiating events in the development of a fatty 
streak. 
 
 
Fig. 2 Initiating events in the development of a fatty streak (from [5]) 
 
13
When monocytes adhere to the endothelial layer, they migrate into the 
subendothelial space and get exposed to cytokines and factors, such as the 
Macrophage colony stimulating factor (MCSF) which leads to macrophage 
differentiation. When monocytes differentiate into macrophages, they upregulate a set 
of proteins, including the so called scavenger receptors. Uptake of modified LDL via 
scavenger receptors leads to foam cell formation [11]. OxLDL cholesterol taken up by 
scavenger receptors, such as scavenger receptor A (SRA), cluster of differentiation 
36 (CD36) or lectin-like oxLDL receptor 1 (Lox-1), amongst others, is subject to 
esterification and storage in lipid droplets.  
 
 
4.1.2 Foam cell formation: balance between cholesterol uptake and efflux 
 
 
An important and characteristic hallmark of both early and advanced 
atherosclerotic lesions is the development of macrophage “foam cells” that contain 
massive amounts of cholesterol esters in the form of lipid droplets. Cholesterol 
accumulation in these cells is due to the uptake of modified forms of LDL through the 
above mentioned scavenger receptors. The recognition of oxLDL by the scavenger 
receptors is through their apo B part [12]. It has been demonstrated that amongst all 
the scavenger receptors involved in lipid uptake, SRA, CD36 and Lox-1 play 
significant roles. Apo E-deficient mice lacking either of these three receptors 
developed less atherosclerosis than control apo-E deficient mice [13]. 
 
Macrophage normally dispose the excess of cholesterol mainly through 
membrane transporters, with HDL serving as the principal extracellular acceptor. In 
vitro studies have broadly indicated that ABC A1 mediates transport of cholesterol 
from cells to HDL acceptors. HDL is esterified to cholesterol esters by lecithin-
cholesterol acyltransferase (LCAT), and it can subsequently exchange cholesterol 
esters for triglycerides carried by other lipoproteins via cholesterol ester transfer 
protein (CETP). Furthermore,  HDL can also deliver cholesterol esters to the liver for 
excretion by binding to the scavenger  receptor SR-B, which also binds HDL. The 
physiologic importance of  SR-B  for reverse cholesterol transport is suggested by the 
findings that hypercholesterolemic mice homozygous for a hypomorphic SR-B1 allele 
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develop increased atherosclerosis, while mice that overexpress SR-B1 exhibit 
reduced atherosclerosis  [14] [15]. Figure 3 depicts foam cell formation and the 
balance between lipid uptake and efflux. 
 
       
Fig. 3 Foam cell formation: balance between lipid uptake and efflux (from [3]) . 
 
The atherosclerotic lesion progresses when interactions between macrophage 
foam cells, Th1 and Th2 cells establish a chronic inflammatory process. Cytokines 
secreted by lymphocytes and macrophages exert both pro- and antiatherogenic 
effects on each of the cellular elements of the vessel wall. Afterwards, smooth muscle 
cells migrate from the medial portion of the arterial wall, they proliferate and secrete 
extracellular matrix proteins which form a fibrous plaque. 
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4.1.3 Inflammation, atheroma progression and complication.  
 
 
When the fatty streak is formed, the early lesion evolves to an advanced and 
complex one which eventually leads to a ruptured stage. Smooth muscle cells 
multiply, accumulate in the plaque and excrete extracellular matrix. As the lesion 
starts growing more and more, the arterial lumen narrows until hinders blood flow and 
leads to clinical manifestations; either unstable angina pectoris, in the coronary 
circulation, or an acute coronary infarction.  
 
This phase of lesion development is characterized by interactions between 
monocyte/macrophages and T cells that result in a broad range of cellular and 
immunological responses and the acquisition of many features of a chronic 
inflammatory state. Cross talk appears to occur among the cellular elements of 
developing lesions. Lesional T cells appear to be activated, expressing both Th1 and 
Th2 cytokines [16]. Similarly, macrophages, endothelial cells, and smooth muscle 
cells get activated and express MHC class II molecules and numerous inflammatory 
products, such as TNFα, IL-6, and MCP-1. Figure 4 depicts lesion progression. 
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Fig. 4 Lesion progression (from [3]) 
The immune responses involved can have both atherogenic and antiatherogenic 
properties. Single cytokines can produce both positive and negative effects.  Interferon γ 
(IFNγ), a Th1 cytokine, can reduce scavenger receptor expression on macrophages, 
decreases collagen synthesis, and inhibit smooth muscle cell proliferation. However, 
IFNγ also stimulates macrophage production of proinflammatory cytokines, increases 
expression of MHC class 2 molecules and accumulation of macrophages within lesions. 
In mice, IFNγ is considered to be atherogenic, as apo E–deficient mice lacking the IFNγ 
receptor showed less atherosclerosis than control apo E–deficient mice [17]. 
Th2-derived cytokines also have an important influence on the atherosclerotic 
lesion. Interleukin-4 (IL-4) can be antiatherogenic by antagonizing INFγ activity in 
macrophages and inhibiting Th1 cell function. However, IL-4  induces 15-LO, which 
promotes LDL oxidation and hence atherosclerosis. IL-10 has deactivating properties in 
macrophages, modulating processes that may interfere with the development and 
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stability of the atherosclerotic plaque. IL-10-deficient mice exhibit an increase in lipid 
accumulation, suggesting the role of IL-10 in reducing foam cell formation [18].  
4.1.4 Advanced lesions and plaque disruption  
 
Macrophages contribute to formation of the necrotic core and thinning of the 
fibrous cap, which characterizes the vulnerable plaque. Thrombosis in the lumen needs 
communication between procoagulant and prothrombotic factors in the intima with 
platelets and coagulation factors in the lumen [5]. Matrix metalloproteinases derived 
from macrophages contribute to fibrous cap thinning. Macrophage-derived serine 
proteases also contribute to the degradation of collagen and elastin in advanced lesions 
[19]. Figure 5 illustrates a advanced lesion and instability of an atherosclerotic plaque. 
Physical disruption of the atherosclerotic plaque may trigger thrombosis and promote the 
expansion of the lesion.  
 
                             
 
Fig. 5 Advanced lesion and instability of the atherosclerotic plaque (from [5] 
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Macrophage apoptosis and ineffective clearance in advanced lesions leads to the 
formation of a necrotic core. Death of smooth muscle cells and protease degradation of 
extracellular matrix weakens the fibrous cap, making it more prone to rupture. Exposure 
of the thrombogenic material in the lesion causes platelet aggregation and the formation 
of thrombi. Macrophages contribute with the overall process secreting cytokines, 
proteases and thrombogenic factors. Myocardial infarctions and strokes are generally 
resulting from plaque rupture and thrombosis, narrowing of the vessels in advanced 
atherosclerotic plaque can lead to isquemia [20]. Furthermore, angiogenesis occurs in 
association with protease activation in surrounding tissues, and it is suggested that 
neovascularization could contribute to plaque instability and rupture [21]. 
 
4.2 Foam cell formation: lipid uptake and efflux 
 
As described before, macrophages loaded with lipid droplets result in cells with a 
foamy appearance becoming the so-called “foam cells” and accumulation of their lipids 
is mediated through scavenger receptors. Release of foam cell contents trigger the 
migration of more macrophages into the intima of the vessel, initiating a vicious cycle in 
the formation of a necrotic core consisting of cell debris, lipids and cholesterol crystals. 
 
Since more than a decade ago, the formation of foam cells has been recognized 
to be important for atherosclerotic development but its mechanism has only been 
studied until recently [22]. It is believed that there are different subsets of macrophages 
which play different roles in atherogenesis. Subsets of macrophages are classified 
according to their surface markers and chemokine receptors, and there are mainly two 
groups:  M1 or classically activated macrophages, and M2 or alternatively activated 
macrophages. M1 macrophages, or classically activated macrophages, are 
characterized generally by interleukin (IL)–12high, IL-23high, IL-10low phenotype. M1 
macrophages produce high amounts of reactive oxygen and nitrogen intermediates as 
well as inflammatory cytokines. Classically activated macrophages are involved in the 
polarized Th1 responses and mediate resistance against intracellular parasites and 
tumors [23]. 
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The M2 type show high levels of scavenger, galactose-like and mannose 
receptors in opposition to M1 or classically activated macrophages. M2 have an 
increased ability to phagocyte tissue debris and prevent tissue damage, compared to the 
other population [24]. Recent studies showed another macrophage subtype, Mox, which 
is found in the oxLDL-rich microenvironment of atherosclerosis. Mox macrophages have 
lower chemotactic and phagocytic capacities. However, these studies have been 
conducted in vitro only, because of the complexity of atherosclerotic lesions regarding 
heterogeneity of macrophages [25]. 
 
Macrophages take up extracellular modified lipoproteins through receptor-
phagocytosis and pinocytosis. Since four years it is believed that the LDL receptor plays 
a major role in this process [26], but foam cells are even found in familiar 
hypercholesterolemia patients with genetically impaired LDL receptors. Deficiency of 
ApoE and CD36 show reduced atherosclerotic lesions compared to their littermate 
controls (ApoE–null mice) demonstrating the importance of scavenger receptors [27]. In 
contrast to LDL receptors, which are known to be down regulated in conditions of 
increased cholesterol, scavenger receptors are not affected leading to continuous 
internalization of lipoproteins which accumulate in the form of lipid droplets in the 
cytoplasm. 
 
When internalized, lipoproteins are delivered to lysosomes where cholesterol 
esters (CE)  get hydrolyzed into fatty acids (FA) and free cholesterol (FC). In lysosomes 
acid lipases hydrolyze CEs and generate FC for the efflux through ABC transporters. On 
the other hand triglycerides are hydrolyzed into glycerol and fatty acids which are then 
esterified again and stored into lipid droplets [24]. 
 
Receptor-mediated free cholesterol efflux is another important mechanism for 
prevention of foam cell formation. Passive diffusion plays a minor role, but active 
transport via several transporters is responsible for the efflux of cholesterol from 
macrophages by ABCA1 and ABCG1 [28]. Besides ABC transporters, also the 
scavenger receptor B (SRB) is atheroprotective because it is involved in cholesterol 
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efflux.  Genetically suppressed SRB in ApoE-deficient mice accelerates dramatically the 
progression of the disease [29].  
 
Moreover, cellular lipid homeostasis is regulated through transcription factors, 
such as sterol regulatory element-binding proteins (SREBPs) and peroxisome 
proliferator-activated receptors (PPARs). SREBPs play a main role in keeping  lipid 
homeostasis and regulate many genes involved in cholesterol homeostasis and fatty 
acid biosynthesis [30] . 
 
 
 
4.3 Scavenger receptors 
 
Scavenger receptors are structurally diverse proteins. When originally identified, 
by Brown and Goldstein in 1977, they were defined by their capacity of binding modified 
forms of low density lipoproteins, including oxidized LDL (oxLDL) and acetylated LDL 
(acLDL) and considered as pro-atherogenic [2]. While native LDL is removed from the 
circulation by the LDL receptor, modified LDL cannot use this pathway and binds to 
scavenger receptors instead, leading to uncontrolled lipid overload and foam cell 
formation [31]. 
 
According to the classification done by Krieger and colleagues [32], the family of 
scavenger receptors includes eight different classes of membrane and soluble proteins 
encoded by different and unrelated genes. Figure 6 shows the members of the 
scavenger receptor family, which are grouped based on their structural domains, rather 
than sequence similarity[33]. 
21
       
 
Fig. 6 Members of the scavenger receptor family (from [31]. 
 
 
Most of the 8 classes of scavenger receptors are implicated in atherogenesis, 
contributing to foam cell formation by interacting with oxLDL or by additional 
mechanisms as described below.   Scavenger receptors perform clearance of unwanted 
macromolecules, pathogens and specially modified  lipoproteins, using receptor 
mediated endocytosis. In general, endocytic receptors recognize extracellular ligands, 
and then invaginates them forming clathrin complexes and vesicles. Vesicles contain 
complexes of receptor-ligand and are delivered to endosomes. Scavenger receptors can 
then dissociate from their ligands and recycle to the surface of the cell where they 
internalize new portions of the ligand. In some cases, scavenger receptors remain 
associated with their ligands and are degraded in lysosomes [31]. 
 
Class A scavenger receptors include four related genes: scavenger receptor A 
(SR-A), macrophage receptor with collagenous structure (MARCO), scavenger receptor 
with C-type lectin (SRCL) and scavenger receptor A-5 (SCARA5) [33]. The SR-A genes 
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produce three (SR-AI/II/III) splice variants. SR-AI and II are largely found on 
macrophages but they can also be present on endothelial cells and vascular smooth 
muscle cells. SR-A is postulated to be proatherogenic because of its capacity to bind 
oxLDL contribuing to foam cell formation. 
 
Class B scavenger receptors contain four members: CD36, SR-B, LIMPII-related 
genes and CD163. CD36 expression includes cells of lymphoid and hematopoietic 
lineages including leukocytes, platelets, endothelial cells, adipocytes, VSMCs and some 
epithelial cells; its levels are highest in macrophages [33].  
 
Class C receptors only includes dSR-C1 which has been so far only found in 
Drosophila melanogaster. dSR-C1 is a pattern receptor for bacteria present in 
hemocytes and macrophages during the embryonic development of the fly. Class D 
includes CD68 and Lamp, a lysosomal membrane glycoprotein. Class E consists of only 
one member: the lectin-like oxidized low density lipoprotein receptor 1 (Lox-1). Lox-1 
(OLR1) is expressed on endothelial cells, macrophages, smooth muscle cells and 
platelets. Its resting levels are low but they are increased by proinflammatory stimuli 
including oxLDL, inflammatory cytokines, TNF-α, shear stress, oxidative stress, phorbol 
ester, endothelin-1 and angiotensin II. Lox-1 activates foam cell formation and the 
incidence of atherosclerotic plaques is significantly lowered in Lox-1-deficient mice. 
Class F consists of the SREC, a scavenger receptor expressed by endothelial cells and 
macrophages. The chemokine ligand CXCL16 is a class G scavenger receptor. It binds 
phosphatidylserine and oxidized lipoprotein (SR-PSOX). Its expression is increased by 
TNF-α, IFN-γ, LPS and oxLDL stimulation. Class H scavenger receptors includes 
fasciclin, EGF-like, lamin type EGF-like and link domain-containing scavenger receptor-1 
(FEEL-1) [33]. 
 
The best investigated scavenger receptors involved in foam cell formation are 
CD36 and SRA. Kunjathoor and coworkers generated mice lacking both SR-A and 
CD36 to investigate their combined impact on macrophage lipid uptake and verify the 
contribution of other SRs to this process. They demonstrated that SR-A and CD36 
account for 75-90% of degradation of LDL modified by acetylation or oxidation. 
23
Cholesteryl ester derived from modified lipoproteins did not accumulate in macrophages 
taken from SRA-CD36 deficient mice. With these results they suggested that SR-A and 
CD36 are responsible for the principal modified LDL uptake in macrophages and that 
other scavenger receptors do not have a relevant compensation when they are absent  
[34].  
 
Kunjathoor demonstrated that both, SRA and CD36, are the main receptors 
responsible for foam cell formation. However, Moore and coworkers showed on the 
other hand, aortic sinus lesions with abundant foam cells in SRA and CD36 knockout 
mice [5]. This finding indicates the relevance of other scavenger receptors in foam cell 
formation as well.  
 
Lox-1 overexpression in transgenic mouse models has been recently studied to 
explore its functional role in atherosclerosis. Inaoe observed that ApoE mice with 
elevated Lox-1 levels displayed accelerated intramyocardial vasculopathy. They showed 
that the increase of Lox-1 in coronary vessels and cardiomyocytes correlated with 
enhanced oxLDL uptake [35]. In vitro studies have shown that oxLDL-mediated 
activation triggers an endothelial Lox-1-linked signaling pathway, leading to pro-
inflammatory responses. Lox-1 activation stimulates ROS production and activates 
nuclear factor κB (NF-κB) which translocates into the nucleus results and activates 
transcription of genes encoding pro-inflammatory and adhesion molecules [36]. Lox-1 is 
transcriptionally upregulated by TNFα, angiotensin II, shear stress and ox-LDL [37]. 
Expression of Lox-1 leads to expression of adhesion molecules, CD40/40 L in 
endothelial cells and upregulation of matrix metalloproteinases [38]. A deeper 
knowledge about the regulation of this receptor and its signal transduction pathways 
may lead to new therapies for pathologies which involve endothelial dysfunction, such as 
atherosclerosis. 
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4.4 Atherosclerosis and hypoxia 
During atherogenesis, the supply of nutrients and oxygen to the inner parts of 
atherosclerotic plaques likely becomes diffusion-limited. Therefore, the balance between 
oxygen supply and demand in the arterial wall is important for plaque progression. As 
the lesions grow and the number of foam cells in the intima increases, the core becomes 
gradually hypoxic and macrophage cellular oxygen consumption is inhibited.  
Normal oxygen tension in tissue ranges from 20–100 mmHg to below 10 mmHg 
in normal liver and kidney [39]. In vitro effects of hypoxia are usually observed between 
10 mmHg (1%, or 14 µM, O2) and 1.6 mmHg (0.2% O2).  Sluimer and coworkers 
demonstrated the presence of hypoxia in advanced atherosclerotic lesions of 
symptomatic patients using pimonidazole administration prior to carotid endarterectomy 
and observed that hypoxia correlates with the presence of macrophages, angiogenesis 
and thrombus formation [40].  Oxygen measurements in vitro and in situ indicated as 
well that the oxygen partial pressure in the core is inversely correlated with the size of 
the plaque [41]. 
Hypoxia is present when oxygen supply is decreased and/or demand is increased 
[42]  In the atherosclerotic lesion, oxygen diffusion may be limited due to intimal 
thickening or obstructed by calcifications. However, hypoxia could also occur because of 
the high oxygen demand of inflammatory cells, such as macrophage foam cells [43]. 
Hypoxia of the vessel wall has been detected when the intimal thickness exceeds the 
maximum oxygen diffusion distance of ׽100–250 µm [40].  In rabbit atherosclerosis 
plaque hypoxia was observed in 200–300 µm deep regions of the rabbit plaque and 
specifically in macrophage-rich areas [41]. In most human lesions, a 100–250 µm 
hypoxia-negative rim bordered the lumen, suggesting that hypoxia resulted from plaque 
thickness [40].   
Nevertheless, hypoxia has been shown to occur in foam cells suggesting that the 
inflammatory content can contribute to the presence of plaque hypoxia. Björnheden 
showed in human subluminal region (20–30 µm) foam cells  that were already hypoxic, 
despite their location still within the oxygen diffusion distance [41]. As described before, 
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inflammation is a hallmark of the atherosclerotic plaque. Hypoxia threshold is as likely to 
be dependent on the inflammatory environment within the plaque. The transcription 
factor HIF, which will be described into more detail in the next section, plays a major role 
in cellular adaptation to hypoxia. It has been shown an important cross-talk between HIF 
hypoxia and inflammation [44]. 
Gao and coworkers reviewed studies which describe the role of HIF in various 
stages and components of atherosclerosis. Figure 7 summarizes the most important 
effects of HIF-1 on atherosclerosis. 
 
Fig. 7 Main pathophysiological effects of HIF-1 in atherosclerosis. Adapted from [45] 
 
As it was described before, the maintenance of vascular homeostasis is 
performed by endothelial cells, as well as the recruitment of inflammatory cells, 
cytokines, and the formation of a barrier with antithrombotic functions. All of these 
mechanisms are perturbed in the presence of hypoxia, because of the regulatory 
pathways controlled by HIFs which can lead to inflammation and angiogenesis.  In 
vitro studies performed by Fang et al., show stabilization of HIF-1α and HIF-2α in 
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macrophages experiencing hypoxia [46] and moreover, Oda and coworkers, 
observed that macrophage differentiation was activated by HIF-1α [47].  
Hypoxia is very closely related to angiogenesis by the presence of intraplaque 
new vessel formation and the implication of several HIF downstream targets such as 
VEGF and matrix metalloproteinases. Microvessels are present in the normal adventitia, 
where they are called ‘vasa vasorum’, and in the atherosclerotic plaque. Like the vessel 
lumen, vasa vasorum supply oxygen to the vessel wall [48].  HIF1α co-localizes with 
hypoxia and macrophages [40] and is related to atherosclerosis and angiogenesis 
development in human coronary and carotid atherosclerosis [40] [49].  
 
4.5 Hypoxia and cellular oxygen sensing 
 
Hypoxia in human physiology and disease 
 
Oxygen tensions in physiological tissue are lower than ambient oxygen tensions 
due to the decrease in the oxygen from the blood as it circulates from the lungs 
throughout the body. Koh et al [50] summarized some physiological oxygen 
concentrations in normal human tissue types. Table 1 describes physiological 
concentrations in normal human tissue samples. 
 
                                
 
Table1. Physiological oxygen concentrations in a selection of normal human tissue 
types. From [50]. 
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 Different oxygen concentrations have major roles in human physiology. For 
instance, hypoxia offers the appropriate stimulus for embryogenesis, wound healing and 
keeps the pluripotency of stem cells. However, it can also restrict physiological functions 
in cells, organs and tissues as when caused by ischemia or by high altitude.  
 
4.5.1 The hypoxia inducible factor: HIF 
Semenza and Wang discovered in 1992 a nuclear factor that was induced under 
hypoxia in human Hep3B hepatoma nuclear extracts. They observed that this protein 
bound to the oxygen-responsive enhancer element of the erythropoietin gene promoting 
its transcription under hypoxic conditions [51]. They cloned the main players which 
enable aerobic organisms to adapt to hypoxia, and called them Hypoxia inducible factor 
(HIF).  
HIFs are highly sensitive to oxygen changes and play a major role protecting the 
body in response to hypoxia. This is achieved through the activation of more than 200 
genes, involved in cellular adaptation to hypoxia, angiogenesis and cell survival [45; 52].  
HIFs are composed of one alpha and one beta subunit, which conform a 
heterodimer. There are three main HIF-α subunits (HIF-1α, HIF-2α or HIF-3α) and a 
constitutive HIF-β subunit, also known as the aryl hydrocarbon receptor nuclear 
translocator (ARNT), which together constitute the HIF-1, HIF-2 and HIF-3 complexes 
respectively [53]. The better studied are HIF-1 and HIF-2; HIF-3 shares with both a Per-
Arnt-SIM (PAS) and a basic helix-loop-helix (bHLH) domains, but is lacking a C-terminal 
transactivation domain (C-TAD).  
 
The bHLH and PAS domains are responsible for heterodimerization and DNA 
binding; on the other hand, the oxygen-dependent degradation (ODD) domain is 
required for oxygen-dependent hydroxylation and degradation. The N-terminal and C-
terminal transactivation domains (N-TAD and C-TAD, respectively), are required for 
transcriptional activation. 
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Fig. 8 The structural domains of the hypoxia-inducible factor. Adapted from [50] 
 
Figure 8 shows the binding domains of some of the known modulators of HIF-α 
(red fonts indicate inhibitory interactions, green fonts indicate activating interactions). 
The von Hippel–Lindau protein (pVHL) E3 ligase complex is known to regulate all three 
HIF-α subunits. The factor inhibiting HIF (FIH) hydroxilates HIF-α subunits [50]. Figure 8 
further depicts that hypoxia-associated factor (HAF) selectively binds to HIF-1α and HIF-
2α, leading to degradation and transactivation, respectively. Hsp70 enhances the 
binding to the carboxy terminus of Hsp70-interacting protein (CHIP) to HIF-1α, resulting 
in HIF-1α degradation. Sirtuin 1 (SIRT1) participates in deacetylation of HIF-2α, resulting 
in its activation [50]. 
In 1996, Jiang and coworkers observed in HeLa cells that HIF-1α levels increase 
exponentially in low oxygen concentrations with a maximal response at 1 to 0.5% O2 
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and maximal HIF levels induced at concentrations below 0.5% O2 [54].   Under normoxic 
oxygen concentrations, HIFα subunits are hydroxylated by prolyl hydroxylase domain 
containing (PHD) enzymes which target HIFα for polyubiquitinilation by the von Hippel-
Lindau protein (VHL) and  proteosomal degradation. However, when oxygen is 
insufficiently available, PHDs are inhibited. This leads to an accumulation of HIFα 
subunits, which translocate into the nucleus, bind to highly conserved hypoxia 
responsive elements (HREs) and activate downstream targets for cellular adaptation to 
hypoxia. Figure 9 illustrates HIF regulation by oxygen. 
 
 
                               
 
Fig. 9 HIF regulation by oxygen. Adapted from [55] 
 
Under aerobic conditions, HIF- subunits are hydroxylated by PHDs at two 
conserved proline residues (P402/P564 and P405/P531 for human HIF-1α and HIF-2α, 
respectively) situated within the ODD domain. Hydroxylation requires oxygen, 2-
oxoglutarate (2-OG), ascorbate, and iron (Fe2+) as cofactors. The hydroxylation of  HIF 
subunits facilitates the binding of  pVHL to the HIF-1/2α ODD [56]. This in turn forms the 
substrate recognition module of an E3 ubiquitin ligase complex comprising elongin C, 
elongin B, cullin-2, and ring-box 1, which directs HIF-1/2α polyubiquitylation and 
proteasomal degradation [57].  
Under hypoxic conditions, PHD activity is inhibited, pVHL binding is blunted, and 
HIF-1α and HIF-2α accumulate and enter the nucleus where they heterodimerize with 
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HIF-β and bind to the HRE to transactivate a variety of hypoxia-responsive genes. As 
mentioned above, in normoxia the ability of HIFs to activate transcription is further 
prevented by another oxygen-regulated enzyme, factor inhibiting HIF-1 (FIH-1). FIH-1 
hydroxylates Asn 803 within the TAD-C of human HIF-1α, disrupting its interaction with 
the transcriptional co-activators p300/CREB-binding protein (CBP) [58]. As with the 
PHDs, Asn hydroxylation is inhibited under hypoxic conditions, allowing the p300/CBP 
complex to bind to HIF-1/2α, allowing HIF transactivation. 
4.5.2 HIF-1 versus HIF-2 activation 
Since its identification over a decade ago, HIF-1α has been described as the 
master regulator of the hypoxic response. HIF-2α was initially identified as the 
endothelial PAS domain protein (EPAS1), an endothelium-specific HIF-α isoform, and 
was therefore considered to have a more specialized function than HIF-1α [59].  
However, HIF-2α is also expressed in brain, heart, lung, kidney, liver, pancreas, and 
intestine, suggesting that it also has a major role in the hypoxia response. 
Now it is well known that both HIF-1α and HIF-2α participate in hypoxia-
dependent gene regulation. Although both HIF-1 and HIF-2 bind to the same HRE 
consensus sequence in the regulatory regions of target genes, DNA binding does not 
necessarily correspond to increased transcriptional activity, suggesting that post-DNA 
binding mechanisms might be required for transactivation [60]. 
In general, HIF-1 preferentially induces genes that encode for glycolytic enzymes, 
such as phosphofructokinase (PFK) and lactate dehydrogenase A (LDHA); those 
involved in pH regulation, such as monocarboxylate transporter 4 (MCT4) and carbonic 
anhydrase 9 (CA-IX); and those that promote apoptosis, such as BCL2/adenovirus E1B 
19kDa interacting protein 3 (BNIP3) and BCL2/adenovirus E1B 19kDa interacting 
protein 3-like (BNIP3L/NIX) [50].  
On the other hand, HIF-2 induces genes that are involved in invasion, including 
the matrix metalloproteinases (MMP) 2, and 13, and the stem cell factor OCT-3/4 [61]. 
However, HIF-2 has also been shown to regulate enzymes in the glycolytic pathway in 
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the absence of HIF-1, and HIF-1 is capable of activating some MMPs, suggesting that 
under some circumstances, HIF-1α and HIF-2α can  substitute for each other. 
Both of HIF isoforms have common target genes, such as the vascular 
endothelial growth factor A (VEGFA) and glucose transporter 1 (GLUT1). Thus, the 
ability of HIF-1 and HIF-2 to activate specific target genes appears to be dependent on 
the context [50]. 
The temporal regulation of HIF-1 and HIF-2 is dependent on the PHDs that 
regulate HIF-1/2α stability. The actions of the PHDs on different HIF isoforms are 
generally not equivalent. It has been shown that PHD2 has relatively more influence on 
HIF-1α than HIF-2α, and PHD3 has relatively more influence on HIF-2α than HIF-1α 
[62]. Moreover, Koivunen and coworkers showed that FIH may act less effectively on 
HIF-2α compared to HIF-1α [63]. Hu et al suggested that the differences in the coding 
sequences of the HIF-α isoforms might also contribute to isoform-specific function [64]. 
Stiehl et al observed in a MCF7 breast cancer cell model a reciprocal induction kinetic of 
HIF-α isoforms.  HIF-1α expression levels were expressed earlier under hypoxia in 
comparison to HIF-2α. After a longer time period HIF-2α levels increased, leading to a 
decreased expression in HIF-1α levels [65]  Taking together, we can think that different 
mechanisms define the activation of HIF-α isoforms in a context dependent manner in 
response to variations in kinetics and oxygen concentrations.  
4.5.3 The prolyl-hydroxylases: PHDs 
 
Some years ago it has been discovered that the ODD domain of HIF-1α was 
hydroxylated at two proline residues (Pro402 and Pro564) by a prolyl-4-hydroxylase [56] 
[66]. Three mammalian prolyl-4-hydroxylases have been identified [67]. PHDs are 
dioxygenases which require both oxygen and 2-oxoglutarate as co-substrates. PHDs 
transfer one oxygen atom onto the proline residues of the HIF-a subunits; the second 
oxygen atom reacts with 2-oxoglutarate, producing succinate and carbon dioxide [68].  
PHDs contain iron bound by two histidine and one aspartic acid residues. In vitro 
function of PHDs requires oxygen and 2-oxoglutarate as cosubstrates with iron(II) and 
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vitamin C serving as cofactors. Although vitamin C deficiency is known to cause the 
collagen-disassembly disease scurvy, it is unclear whether cellular oxygen sensing is 
similarly affected. Nytko et al., report that vitamin C-deprived Gulo(-/-) knockout mice 
show normal HIF-dependent gene expression. They observed that hypoxic HIF induction 
was also essentially normal under serum- and vitamin C-free cell-culture conditions, and 
suggested that vitamin C is not required for oxygen sensing in vivo. They showed that 
glutathione was found to fully substitute for vitamin C requirement of all 3 PHD isoforms 
in vitro [69].  
The first discovery of a PHD was made  in  the worm Caenorhabditis elegans and 
was called egg-laying abnormal-9 (EGL-9) [67]. In mammals, three different isoforms 
were discovered: PHD1 (HPH3, EGLN2), PHD2 (HPH2, EGLN1) and PHD3 (HPH1, 
EGLN3). PHD1-3 differ in size, intracellular localization and tissue distribution [70]. The 
two modified prolines that constitute the ODD interact separately with pVHL 
complex[71]. Interestingly, in vitro experiments showed that the different PHDs have 
different preferences for the two target prolines in the HIF-ODD [62].  
 
There is an additional fourth PHD-related protein (PH-4) which has been  
reported to hydroxylate the two critical prolyl residues of the HIFα subunit. However, 
unlike the other three PHDs which localize to the cytoplasm and nucleus, PH4 was 
found to be associated with the endoplasmic reticulum (ER) [72] [73]. 
. 
4.5.4 Alternative mechanisms stabilizing HIF-1α under normoxic conditions 
Besides the above mentioned mechanisms of hypoxic HIF α subunit stabilization, 
many growth factors and cytokines are known to stabilize HIF-1α under normoxic 
conditions. These include insulin, insulin-like growth factors 1 and 2, epidermal growth 
factor, fibroblast growth factor 2, interleukin 1β, tumor necrosis factor α, angiotensin II, 
thrombin, transforming growth factor β1, platelet-derived growth factor, and hepatocyte 
growth factor [68]. 
Molecular oxygen nitric oxide (NO) is also a mediator of the inflammatory 
response. NO can regulate HIF-1α accumulation, activity and HIF-1 dependent target 
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gene expression [74]. NO regulates HIF-1 by modulating the activity of the oxygen-
sensor enzymes PHDs and FIH-1. NO dependent HIF-1alpha accumulation under 
normoxia occurs because of direct inhibition of PHDs and FIH-1 most likely by 
competitive binding of NO to the ferrous iron in the catalytically active center of the 
enzymes [74]. 
4.5.5 HIF-1 target genes involved in vascular biology 
 
The increase in angiogenesis leads to an enhancement in the vascular density 
and hence to a decreased oxygen diffusion distance. Moreover, blood flow is controlled 
by modulation of the vascular tone through production of HIF-1 target genes such as  
iNOS (inducible nitric oxide synthase), HO-1 (heme oxygenase 1), endothelin 1, 
adrenomedullin, or activation of the α1B-adrenergic receptor. (reviewed in [68]). 
The heart is subjected to hypoxic conditions during ischemia-reperfusion injury, 
atherosclerosis or during heart failure. One of the first experimental studies which tried 
to investigate HIF-1α stabilization was performed in a HL-1 cardiac muscle cell line, 
which showed an increase in mRNA and protein levels of HIF-1α after exposure to 1% 
O2 after 4 hours [75]. HIF-1 mRNA and protein upregulation was confirmed in both, 
neonatal hearts and in cardiomyocytes subjected to chronic hypoxia [76] and 
furthermore, myocardial HIF-1α mRNA expression was shown to be increased in 
response to acute ischemia or infraction in human myocardial biopsies from patients on 
coronary artery bypass (CABG) surgery [77]. 
 
4.6 Hypoxia and foam cell formation 
 
Accumulation of cytosolic lipid droplets is caused by increased intracellular 
cholesterol derived from oxLDL uptake. Hypoxia increases lipid accumulation in 
macrophages even in the absence of lipoproteins  because of increased triglyceride 
biosynthesis  [78]. siRNA studies blocking HIF-1α have shown to block  foam cell 
formation indicating a role for HIF-1α in lipid accumulation [79]. However, the 
underlying mechanism is poorly understood. A recent study highlighted the 
34
importance of Glut-3 for the de novo lipogenesis in hypoxia-induced lipid loading of 
human macrophages [80]. Hypoxia increases glucose uptake through GLUT3 
required for lipid synthesis in macrophages which may contribute to foam cell 
formation in hypoxic regions of atherosclerotic lesions.  
 
Sterol regulatory element binding protein (SREBP) has been shown to be 
upregulated in response to low oxygen [81], as well as the SREBP cleavage-
activating protein [82], liver receptor X (LXR)[83], the adipocyte differentiation-related 
protein and peroxisome proliferator-activated receptors (PPARs) [84].  
 
Another angiogenic chemokine, interleukin-8 (IL-8), is upregulated by foam 
cells located in hypoxic areas of rabbit and human atherosclerotic plaques [85]. 
Secretion of IL-8 leads to the recruitment of smooth muscle, vascular endothelial and 
T cells into the atherosclerotic plaques.  Rydberg and coworkers showed that 
macrophages exposed to hypoxia up-regulate the expression of lipooxygenase-2, an 
enzyme implicated in low-density lipoprotein oxidation. Furthermore,  Wüst et al., 
observed that ALOX15B is the mainly expressed 12/15-lipoxygenase in human 
macrophages and that its expression is induced by IL-4, LPS, and hypoxia [86].  
 
  Another evidence which shows that hypoxia contributes to lipid metabolism in 
atherosclerotic lesions is that under low concentrations very low-density lipoprotein 
(VLDL) receptors are upregulated on macrophages [87]. The VLDL receptor mediates 
the uptake of β-VLDL, chylomicron remnant, and lipoprotein LP(α), contributing to 
foam cell formation. 
 
Several other genes have been shown to be up-regulated by foam cells in 
response to hypoxia. One of them is oxygen-regulated protein 150 (ORP150), whose 
expression is restricted to foam cells within atherosclerotic lesions  [88]. The precise 
biological function of ORP150 is not clear yet, but has been suggested to be linked to 
macrophage survival in hypoxia [89]. This work proposes that ORP150 may protect 
foam cells from hypoxia induced stress allowing them to carry out their role of 
cholesterol scavenging and tissue remodeling in atherogenesis.  
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 The macrophage migration inhibitory factor 1 (MIF) has also been shown to be 
highly expressed by foam cells in atherosclerotic lesions [90]. MIF has been shown to 
mediate proliferation of cultured endothelial cells [91], so it is likely that in plaques it 
can also promote neovascularization. Moreover, treatment of  ApoE-deficient mice 
with neutralizing anti-MIF antibodies, reduced a variety of inflammatory mediators  
which are normally associated with  atherogenesis, implying that MIF may also play 
an important role in intima inflammation [92].  
 
Aggregated  LDL (agLDL) stimulates foam cell formation by inducing cholesteryl 
ester accumulation in lipid droplets. It has been demonstrated recently that agLDL can 
be internalized by the LDL receptor-related protein (LRP1), which has been also recently 
shown to be hypoxically induced [93]. 
 
Many cytokines and enzymes are induced in hypoxic foam cells within human 
atherosclerotic plaques, such as  VEGF [94] , platelet-derived growth factor (PDGF) 
[95], TNF-α [96], and others. However, the expression of these factors by hypoxic 
foam cells in comparison to non hypoxic foam cells in vivo has yet to be determined. 
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5. Aims of the study  
 
I. Determine the effect of hypoxia on genes involved in lipid metabolism, 
particularly genes related to cholesterol uptake and efflux. 
 CD36. 
gradients. 
II. Explore if hypoxia plays a role in lipid uptake and in foam cell formation 
through the scavenger receptors SRA, Lox-1 and
III. Investigate cells and pathways linking HIF-1α to lipid metabolism and to 
scavenger receptor expression under hypoxia. 
IV. Characterize human atherosclerotic plaques, for hypoxia markers and 
scavenger receptors within the tissue oxygen 
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Abstract   
Aims Advanced atherosclerotic plaques turn hypoxic in their core as the arterial wall 
thickens and oxygen diffusion capacity becomes impaired. Macrophage-derived foam cells 
in atherosclerotic lesions play a pivotal role in plaque formation by expressing scavenger 
receptors that regulate lipid uptake. However, the role of hypoxia in scavenger receptor 
regulation remains incompletely understood.  
Methods and Results Using RT-qPCR, flow cytometry, and immunoblotting, we found 
that mRNA and protein expression levels of the scavenger receptor A (SRA) and the 
cluster of differentiation 36 (CD36) were upregulated by oxidized low-density lipoprotein 
(oxLDL), but decreased following exposure of macrophages to hypoxia. In contrast, lectin-
like oxLDL receptor (Lox-1) mRNA and protein levels were upregulated under hypoxic 
conditions. Flow cytometry confirmed the increased lipid content in macrophages after 
exposure to 0.2% oxygen and the hypoxia mimetic dimethyloxalylglycine (DMOG). 
Antibody-mediated blocking of Lox-1 receptor decreased the hypoxic induction of lipid 
content and oxLDL uptake. RNAi-mediated knock-down of hypoxia inducible factor 
(HIF)-1α in macrophages altered the expression of SRA and Lox-1 receptors in hypoxia, 
suggesting that HIF-1α mediates their modulation by hypoxia.  
Conclusions Thus, hypoxia differentially regulates the expression of the three oxLDL 
receptors Lox1, SRA, and CD36. Lox-1 plays a role in hypoxia-induced foam cell 
formation. 
 
Keywords Atherosclerosis, foam cell, hypoxia-inducible factor, oxLDL 
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Introduction 
Atherosclerosis is the major cause of myocardial infarction and stroke and the leading 
cause of mortality in Western countries. It results from the interaction between oxidized 
low-density lipoproteins (oxLDL), activated endothelial cells, monocyte-derived 
macrophages, and the vessel wall. Transmigration of monocyte-derived macrophages into 
the subendothelial space is a key step in atherogenesis. Pro-inflammatory macrophages 
ingest oxLDL via scavenger receptors and become foam cells, thereby promoting plaque 
formation [1]. Upon plaque thickening with progression of atherosclerosis, the supply of 
nutrients and oxygen to the inner parts of atherosclerotic plaques becomes diffusion-
limited. As the lesions grow in thickness and the number of foam cells in the intima 
increases, the plaque core becomes gradually hypoxic and macrophage cellular oxygen 
consumption is inhibited. Sluimer and coworkers demonstrated the presence of hypoxia by 
pimonidazole staining of advanced atherosclerotic lesions in symptomatic patients [2]. 
Oxygen measurements in vitro and in situ indicated that the oxygen partial pressure in the 
core inversely correlates with the size of the plaque [3]. 
 Hypoxia-inducible factor (HIF) is the main stimulator of oxygen-regulated gene 
expression. Hypoxia inhibits oxygen-dependent HIF prolyl-4-hydroxylases (PHDs), 
leading to the rapid stabilization of HIF α-subunits [4]. In macrophages, oxygen sensing 
and inflammation cross-talk via NF-κB-induced transcription of the HIF1A gene [5]. 
While these two conditions are well known to contribute to tumor progression, much less 
is known about their role in atherosclerosis. As in solid tumors, hypoxia and inflammation 
are increased in the center of atherosclerotic plaques, where they trigger angiogenesis and 
plaque growth. Plaque-derived cytokines, growth factors, and increased endothelial 
adhesion molecules recruit monocytes to the activated endothelium, promote 
transmigration to the subendothelial space, and induce their transdifferention into 
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macrophages. This step is crucial for the progression of atherosclerosis and is associated 
with up-regulation of pattern-recognition receptors for innate immunity, including 
scavenger receptors and toll-like receptors. Scavenger receptors internalize a broad range 
of molecules and particle-bearing molecules with pathogen-like molecular patterns. 
Bacterial endotoxins, apoptotic fragments and oxLDL particles are all taken up and 
destroyed via this pathway. If cholesterol-derived uptake of oxLDL particles cannot be 
sufficiently mobilized from the cell, it accumulates as cytosolic droplets [1]. Ultimately, 
macrophages are transformed into foam cells, a hallmark of atherosclerotic lesions.  
 It has been previously reported that exposure of human macrophages to hypoxia 
activates proinflammatory pathways such as the Akt and the beta-catenin pathway[6]; 
moreover, hypoxia favors accumulation of lipid droplets and HIF-1α knock-down inhibits 
foam cell formation in vitro [7; 8]. Foam cell formation is a characteristic event for both 
early and late atherosclerotic lesions [9]. Although a number of proteins may contribute to 
this process, scavenger receptors A (SRA), lectin-like oxLDL receptor (Lox-1) and cluster 
of differentiation 36 (CD36) have been demonstrated to be most relevant [10]. In retinal 
pigment epithelial cells, mRNA and protein levels of CD36 have recently been shown to 
be upregulated by hypoxia [11]. Furthermore, decreased SRA upregulation by oxLDL and 
increased LDL receptor-related protein-1 (LRP1), respectively, have been found after 
hypoxic exposure [12].  
 Taken together, the data regarding foam cell formation and the associated pathways 
in hypoxic macrophages remain conflicting. Thus, we explored the mechanisms by which 
hypoxia affects the expression of the three main scavenger scavenger receptors SRA, Lox-
1, and CD36. We provide evidence for a differential expression of these three scavenger 
receptors in hypoxic macrophages, thereby demonstrating the importance of impaired 
oxygen supply for the progression of atherosclerotic plaques.  
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Methods 
 
Cell culture 
Mouse RAW264.7 leukemic monocyte cells and Hepa1 hepatoma cells were grown in 
DMEM (Sigma). Media were supplemented with 10% fetal calf serum (FCS) and 
antibiotics (50 IU/ml penicillin and 100 μg/ml streptomycin; Sigma-BRL). If not indicated 
otherwise, hypoxic cell culture was carried out at 0.2% O2 using a gas-controlled InvivO2 
400 workstation (Ruskinn Technologies). Cells were treated with 1 mM of the pan PHD 
inhibitor dimethyloxalylglycine (DMOG) or dimethylsulfoxide (DMSO) as solvent 
control. RAW264.7 cells were treated with 10 μg/mL oxLDL, acLDL, DiL-oxLDL or 
DiL-acLDL (KalenBiomed) as indicated. 
 
Protein extraction and immunoblot analysis 
Total soluble cellular proteins were extracted with a high salt extraction buffer containing 
0.4 M NaCl, 0.1% Nonidet P-40, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail 
(Sigma). Protein concentration was determined by the BCA method and 50 to 70 μg of 
cellular protein was subjected to immunoblot analysis. PVDF membranes were probed 
using the following dilutions of mouse monoclonal (mAb), rat monoclonal (ratAb) or 
rabbit polyclonal (rAb) antibodies: mAb HIF-1α (1:1000; BD Transduction Laboratories), 
ratAb SRA (1:1000 AbD Serotec), mAb β-actin (1:5000; Sigma), rAb PHD2 (1:1000; 
Novus), rAb Lox-1 (1:1000; R&D Systems), rAb Glut-1 (1:1000; Abcam) or rAb CD36 
(1:1000; Abcam), followed by secondary HRP-conjugated antibodies (1:2000; Pierce). 
Chemiluminescence signals were developed using Supersignal West Dura substrate 
(Pierce) and images were acquired with a digital light imaging system (LAS 4000; Fuji). 
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 mRNA quantification 
Total RNA purification and mRNA determination by reverse-transcription quantitative 
PCR (RT-qPCR) using SYBR Green qPCR reagent kit (Sigma) in combination with an 
MX3000P light cycler (Stratagene) has been described previously [13]. Initial copy 
number of each sample was calculated by comparison with serial dilutions of a calibrated 
standard. β-Actin mRNA was used as a housekeeping control for mouse cell lines. Primer 
sequences are listed in supplemental Table 1.  
 
Plasmids and siRNA transfection 
Cells were transfected with 100 nM siRNA  duplex oligonucleotides (Invitrogen) by 
electroporation (Amaxa Biosystems). Therefore, pelleted cells were resuspended in fresh 
medium and counted using a ViCell counter (Coulter). Per transfection, 4 x 106 cells were 
transferred to a fresh tube and centrifuged at 90 x·g for 10 minutes. After carefully 
removing the supernatant, the cell pellet was resuspended in 100 μL Mouse Macrophage 
Nucleofector Solution with supplement (Amaxa Biosystems). siRNA (2 μg) or endotoxin-
free pmaxGFP plasmid DNA (Amaxa Biosystems) as transfection control was added and 
the cells electroporated (Amaxa Nucleofector II, program D-032). Immediately afterwards, 
cells were diluted in 0.2 mL of DMEM and transferred to 10 cm cell culture dishes. The 
following forward siRNA oligonucleotides were used: HIF-1α siRNA, 5′-
UCUCCAAGCAUCUUCUCAAUGUUUC-3′; control siRNA, 5′-
UAAUACUCUGGUAGUUCUCCGGAGC-3′. 
 
 
 
50
Short hairpin RNA constructs and lentiviral infections 
Expression vectors encoding short hairpin RNA (shRNA) sequences targeting mouse HIF-
1α and a noncoding control driven by the U6 promoter in a pLKO.1-puro plasmid were 
purchased from Sigma. Viral particles were produced in HEK293T cells using the 
ViraPower lentiviral expression system according to the manufacturer's instructions 
(Invitrogen). 
 
Flow cytometry 
Single cell suspensions were incubated with antibodies against SRA, Lox-1 and CD36. 
Immune complexes were visualized by FACScanning using goat anti-rabbit antibody-
Alexa 488 for CD36 and Lox-1, or with goat anti-mouse antibody-Alexa 488 for SRA 
(Molecular Probes, Invitrogen). For lipid uptake experiments, RAW264.7 cells were 
seeded in six-well dishes, starved with 0.2% FCS in DMEM for 24 hours, and incubated 
with or without 10 μg/mL oxLDL, DiL-oxLDL, DiL-acLDL or acLDL for 24 hours at 
21% or 0.2% oxygen. To block Lox-1, RAW264.7 cells were pre-incubated with 5 μg/mL 
anti-Lox-1 blocking antibody (RD systems) for 24 hours. Lipids were stained with 1-2 μM 
1,1'-dioctadecyl-6,6'-di(4-sulfophenyl)-3,3,3',3'-tetramethylindocarbocyanine (SP-
DiIC18(3)) fluorescent probe (DiL) or 3,3´ -dioctadecyloxacarbocyanine perchlorate (DiO) 
for 4 hours. The cells were washed twice with PBS and analysed with a FACSCantoII and 
FACSDiva software (BD Pharmingen). Post-acquisition analysis was done with FlowJo7 
software (Tree Star). Alternatively, DiL-stained lipids were visualized by fluorescent 
microscopy using an Olympus BX51 microscope and analySIS software (Olympus).  
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Lipoprotein uptake 
RAW264.7 cells were starved for 24 hours and then incubated with 10 μg/mL oxLDL for 
24 hours under normoxic or hypoxic conditions as described above. After washing, cells 
were fixed with 4% paraformaldehyde and stained with Oil red O (ORO; Sigma). ORO 
staining was analysed by light microscopy and quantified using analySIS software 
(Olympus). LDL uptake was quantified as the ratio between the ORO-positive area divided 
by the number of cells. 
 
Statistics 
If not otherwise indicated, results are presented as mean valuesԜ±Ԝstandard error of the mean of 
at least three independent experiments. Column statistics applying paired Student's t-tests 
were calculated using GraphPad Prism version 4.0 (GraphPad Software). 
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Results 
 
Hypoxia regulates genes involved in cholesterol transport 
To elucidate whether hypoxia affects the expression of genes involved in cellular 
cholesterol flux, wild-type Hepa1 or HIF-β mutant Hepa1C4 mouse hepatoma cells as well 
as RAW264.7 mouse macrophages were analyzed for oxygen-dependent expression of 
candidate genes involved in cholesterol transport. Exposure of these cell lines to pro-
inflammatory oxLDL under normoxic (20% O2) or hypoxic (0.2% O2) conditions for 24 
hours revealed that hypoxia increased mRNA levels of candidate genes such as Lox-1, 
ABCA1 and ABCG1 cholesterol transporters, sterol-regulated element binding protein 
(SREBP) and SREBP cleavage activating protein (SCAP), but decreased mRNA levels of 
SRB, SRA and CD36 (Figure 1A). Experiments performed in Hepa1C4 cells suggested 
that the increased expression of SREBP, SCAP, ABCA1, ABCG1 is HIF-dependent, 
whereas Lox-1 induction is HIF-independent (Figure 1A). Hypoxia attenuated oxLDL-
induced SRA, CD36, and SRB, but only SRB attenuation appeared to be at least partially 
HIF-dependent (Figure 1A). The established HIF target gene PHD3 was included as 
positive control.  
 Using immunoblotting (Figure 1B) and FACS analysis (Figure 1C) we could 
confirm these findings on the protein level. SRA was not detectable in Hepa1 cells (data 
not shown) and SRA induction by oxLDL in RAW264.7 cells was less clear on the total 
protein than on the mRNA level (Figure 1B). However, surface SRA was again induced by 
oxLDL under normoxic but not hypoxic conditions (Figure 1C, left panel). Hypoxia also 
attenuated total CD36 protein (Figure 1B) but, surprisingly, induced surface CD36 levels 
(Figure 1C, right panel). 
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HIF-1α mediates hypoxic induction of Lox-1  
In contrast to SRA and CD36, we found a robust hypoxic induction of Lox-1 mRNA in 
Hepa1 and RAW264.7 cells. On the protein level, both hypoxia and DMOG, but not 
oxLDL or acLDL, induced Lox-1 in RAW264.7 cells (Figure 2A). FACS experiments 
confirmed the hypoxic induction of Lox-1 surface protein expression (Figure 2B). 
 The involvement of HIF-1α in the hypoxic regulation of scavenger receptors was 
assessed by RNA interference in RAW264.7 cells. Lentiviral transduction with shRNA 
expression vectors yielded a robust HIF-1α downregulation with shHIF-1α but not with a 
control shRNA (Figure 2C). HIF-1α knock-down abolished hypoxic Lox-1 induction and 
prevented SRA, but not CD36 reduction (Figure 2C).  
 
Hypoxia and DMOG increase lipid content in RAW264.7 macrophages 
The differential regulation of the three main scavenger receptors does not allow any 
prediction of how lipid uptake and content change under hypoxic conditions. Therefore, 
lipid content was determined in RAW264.7 cells by the fluorescent dye DiL following 
exposure to 0.2% oxygen, DMOG and/or oxLDL for 24 hours. DiL and DiO stained cells 
were analysed by fluorescent microscopy (Figure 3, upper left panels) and flow cytometry 
(Figure 3, middle panels).  Oil Red O (ORO) staining was visualized by light microscopy 
and used for comparison (Figure 3, lower left panels). Both hypoxia (Figure 3A) and 
DMOG (Figure 3B) increased the lipid content in RAW264.7 cells already in the absence 
of oxLDL. Exposure to oxLDL further increased the lipid content (Figure 3C).  
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Lox-1 is necessary for lipid uptake in RAW264.7 cells 
To assess the role of hypoxic Lox-1 induction, RAW264.7 cells were treated with anti-
Lox-1 blocking antibodies prior to exposure to hypoxia. Total lipid content was determined 
by DiL (Figure 4A) and ORO staining (Figure 4B), as well as by DiO staining and flow 
cytometry (Figure 4C, left panel). To analyse lipid uptake directly, RAW264.7 cells were 
treated with fluorescently labeled DiL-oxLDL, exposed to 0.2% oxygen, and evaluated by 
flow cytometry (Figure 4D, left panel). Demonstrating the relevance of Lox-1, both 
hypoxia induced lipid content and uptake was attenuated by anti-Lox-1 blocking 
antibodies.  
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Discussion 
 
 Foam cell formation, a hallmark of atherogenesis, is likely to occur under hypoxic 
conditions as a consequence of decreased oxygen diffusion to the core of the plaque. Lipids in 
macrophages include cholesteryl esters and triglycerides which are stored in lipid droplets 
within the cytosol. Lipid accumulation is mainly due to the uptake of modified lipoproteins, 
such as oxLDL and acLDL. Hypoxia has been previously reported to lead to lipid 
accumulation in macrophages even in the absence of lipoproteins [7], and Glut3, a 
downstream target of HIF-1, has been suggested to be required for de novo lipogenesis in 
hypoxia-induced lipid loading of human macrophages [14]. Furthermore, fatty acid synthase 
is upregulated by hypoxia via Akt and sterol regulatory element binding protein-1 [15], 
suggesting a contribution of lipid synthesis to hypoxic foam cell formation. 
We found induction of both, lipid content and oxLDL uptake following exposure of 
RAW264.7 macrophages to hypoxia. Our data suggest a hypoxic switch from SRA and CD36 
to the Lox-1 scavenger receptor that increases on the mRNA and protein levels, and which 
mediates at least in part the increased lipid uptake under hypoxic conditions 
 While HIF-1α is usually not directly involved in gene repression, hypoxic SRA but 
not CD36 downregulation were HIF-1α-dependent. SRA protein regulation was further 
studied by the pan-PHD inhibitor DMOG which also reduced SRA mRNA and protein 
levels in RAW264.7 cells (data not shown). The hypoxic SRA reduction persisted for 24 
hours of milder hypoxia (0.5% or 1% oxygen), and SRA levels partially recovered after 48 
hours hypoxia (data not shown). Since HIF-1α levels were also reduced after 48 hours 
hypoxia, these data additionally support an involvement of HIF-1α in SRA repression. A 
putative hypoxia response element (HRE) was found in the SRA promoter at position -578 
(data not shown), but whether HIF-1 represses SRA by direct promoter binding is currently 
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unknown. In line with our results, SRA protein levels have been shown to be inhibited by 
1% O2 and CoCl2 in RAW264.7 cells [12]. 
 CD36 protein was slightly reduced under hypoxic conditions, whereas flow 
cytometry experiments demonstrated an induction on the cell surface, suggesting CD36 
relocalization in hypoxia. Evidence for hypoxic CD36 translocation to the plasma 
membrane has been found in cardiac myocytes [16]. However, conflicting data have been 
reported about the hypoxic regulation of total CD36: whereas CD36 was increased under 
low oxygen concentrations in human dermal microvascular endothelial cells, human retinal 
pigment epithelial and pulmonary artery smooth muscle cells [11], other studies 
demonstrated a decrease of CD36 expression following hypoxic exposure of adipocytes 
[17]. Therefore, hypoxic CD36 regulation is likely to be cell type specific. 
 To the best of our knowledge, our study is the first one to demonstrate the 
importance of hypoxia-induced Lox-1 for lipid uptake in macrophages. Hypoxia-
reoxygenation of cardiomyocytes has been reported to induce Lox-1 [18], but there are no 
other previous studies on the effects of hypoxia on Lox-1 expression. Lox-1 was first 
identified as a scavenger receptor for binding and uptake of oxLDL in endothelial cells, 
and it has been shown that Lox-1 plays important roles in pro-inflammatory signaling and 
atherogenesis [19]. A cross-talk between hypoxia and inflammation has been further 
supported by the finding that both TNF-α and NF-κB upregulate Lox-1 expression [20].  
 We found Lox-1 to be required for uptake of oxLDL under hypoxic conditions. 
However, hypoxia only slightly stimulated the uptake of acLDL which was not affected by 
treatment with a blocking anti-Lox-1 antibody (data not shown). These observations 
suggest that Lox-1 mediates mainly to the uptake of LDL oxidatively modified by an 
inflammatory milieu. Bioinformatic analysis identified a putative HRE in the Lox-1 
promoter at position -114 (data not shown) which might mediate the HIF effect. 
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In hypoxic macrophages Lox-1 is upregulated, whereas SRA and CD36 are 
decreased.  Thus, we propose that HIF-1α is involved in both SRA inhibition and in Lox-1 
upregulation, thereby enhancing oxLDL uptake. 
 We speculate that with progression of atherosclerotic lesions, the core of the human 
plaques becomes gradually more hypoxic, accelerating foam cell formation in thick 
atheromata during advanced stages of atherogenesis. Pharmacologic inhibition of Lox-1 
may be an attractive therapeutic option for inhibition of foam cell formation – with and 
without hypoxia – i.e. during early and late stages of atherogenesis. 
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Figure legends 
 
Figure 1 Expression patterns of candidate genes involved in oxygen-regulated 
cholesterol transport. (A) Heat maps showing the transcript levels of wild-type Hepa1 
and HIF-β mutant Hepa1C4 as well as RAW264.7 cells exposed to pro-inflammatory 
oxLDL at the indicated oxygen concentrations for 24 hours. Transcript levels were 
determined by RT-qPCR and normalized to β-actin mRNA levels. (B) Immunoblotting and 
(C) FACS analysis of SRA and CD36. RAW264.7 cells were exposed to oxLDL and/or 
DMOG as indicated and exposed to 21% or 0.2% O2 for 24 hours. DMSO was used as 
solvent control. 
 
Figure 2 HIF-1α-mediated upregulation of Lox-1 in hypoxia. (A) Immunoblotting of 
CD36 and Lox-1 in RAW264.7 cells exposed to oxLDL or acLDL and/or 0.2% oxygen or 
DMOG for 24 hours. (B) FACS analysis of Lox-1 expression on RAW264.7 cells exposed 
to oxLDL and/or 0.2% oxygen. (C) Immunoblotting of SRA, CD36, and Lox-1 in 
RAW264.7 cells following shRNA-mediated knock-down of HIF-1α (shHIF-1α) and 
treatment as above. Lentiviral particles containing a noncoding shRNA were used as 
control (shControl). DMSO was used as solvent control in all experiments. 
 
Figure 3 Increased lipid content in macrophages under hypoxic conditions. 
RAW264.7 cells were starved in 0.2% FCS for 24 hours, followed by exposure to (A) 
hypoxia, (B) DMOG or DMSO solvent control, or (C) oxLDL with and without hypoxia. 
Lipid staining was performed with DiL (4 hours) or Oil Red O (ORO) (24 hours) as 
indicated, and detected by fluorescence and light microscopy, respectively (left panels) 
DiL fluorescence was also quantified by FACS (right panels) and evaluated using the folds 
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of induction of median fluorescence values. Oil red O and fluorescent microscopy data 
were quantified dividing positive stained area per number of cells. Results are presented as 
mean valuesԜ±Ԝstandard error of the mean of at least three independent experiments. 
Column statistics applying paired Student's t-tests were calculated using GraphPad Prism 
version 4.0 (GraphPad Software). FACS data were quantified and statistically evaluated 
using the folds of induction of median fluorescence values.  
 
Figure 4 Requirement of Lox-1 for lipid uptake in RAW264.7 macrophages. RAW264.7 
cells were starved in 0.2% FCS for 24 hours, and incubated with or without oxLDL for 24 
hours at 20% or 0.2% oxygen, respectively. Where indicated, Lox-1 was blocked previously 
by treatment with anti-Lox-1 antibodies for 24 hours. To determine lipid content, the cells 
were stained with DiO (A) or Oil Red O (ORO) (B) for 4 and 24 hours respectively, and 
analyzed by fluorescence microscopy (A), light microscopy (B) and FACS (C), respectively. 
(D) To determine lipid uptake, untreated or anti-Lox-1 treated RAW264.7 cells were 
incubated with DiL-labelled oxLDL (DiL-oxLDL) for 24 hours and analyzed by flow 
cytometry. (C, D) Oil red O and fluorescent microscopy data were quantified dividing 
positive stained area per number of cells. Results are presented as mean valuesԜ±Ԝstandard 
error of the mean of at least three independent experiments. Column statistics applying paired 
Student's t-tests were calculated using GraphPad Prism version 4.0 (GraphPad Software). 
FACS data were quantified and statistically evaluated using the folds of induction of median 
fluorescence values (right panels). 
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Supplementary data 
Supplemental Table 1. Primers used for RT-qPCR to quantitate mRNA levels of genes 
involved in oxygen regulated cholesterol uptake and efflux. 
 
Lox-1 F TCTTCCATGGGCCCTTTAGCTG 
Lox-1 R TTCCGATGCAATCCAATCCAGA 
LXR  F AGCAGCTGGGCATGATCGAGAA 
LXR  R AAGTGGGCAAAGCGCTGTTGTC 
Scap F CCTGCAGGTTTGGTGCGCCT 
Scap R GGGGCTTGCCACCCATTGCT 
SR-A F AAAGAAGAACAAGCGCACGTGG 
SR-A R GAGCACCAGGTGGACCAGTTTG 
CD36 F TCCTATTGGCCAAGCTATTGCG 
CD36 R CACGGGGATTCCTTTAAGGTCG 
ABCA1 F ATAGTGTGGAGCTGCCCCATCA 
ABCA1 R CCACATCCTGCAAGTAGGCGAA 
PHD3 F CAACTTCCTCCTGTCCCTCA 
PHD3 R GGCTGGACTTCATGTGGATT 
ABCG1 F GATTGG GAATGAAGCCAAGA 
ABCG1 R GCTGGGACGTCATCCAGTAT 
SREBP F CACGGTACCAGCAATGGAC 
SREBP R CAGATAGCAGGATGCCAACA 
β-Actin F GAGCGTGGCTACAGCTTCAC 
β-Actin R GGCATAGAGGTCTTTACGGATG 
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Objectives: Atherosclerosis is a chronic disease characterized by two main features, lipid retention and
inﬂammation. The 12/15-lipoxygenases play a two-faced role in atherosclerosis with pro-inﬂammatory
effects through oxidation of LDL and anti-inﬂammatory effects through lipid mediator synthesis. In
cells involved in atherosclerosis the 12-lipoxygenase ALOX12 and the two 15-lipoxygenases, ALOX15 and
ALOX15B may be expressed but their expression has not yet been investigated in detail.
Methods: To investigate the regulation of ALOX12, ALOX15 and ALOX15B in human macrophages we
measured basal mRNA and protein expression during differentiation of monocytes to macrophages and
stimulated expression in macrophages.
Results: The results show an increase of ALOX15B during the differentiation of monocytes to macro-
phages, while the expression of ALOX12 and ALOX15 remains on the same low level. Stimulation of
macrophages with a set of cytokines and with hypoxia revealed that IL-4, IL-13, LPS and hypoxia further
increase the ALOX15B mRNA. Western blot analysis showed that IL-4, LPS and hypoxia increase the
ALOX15B protein expression, whereas IL-13 has no effect on the protein levels. IL-4 and IL-13 also
enhance ALOX15 mRNA and protein expression, whereas none of the stimuli has an impact on ALOX12
expression.
Conclusion: In summary, these data suggest that ALOX15B is the mainly expressed 12/15-lipoxygenase in
human macrophages and that its expression is induced by IL-4, LPS and hypoxia. IL-4 and IL-13 also
increase the expression of ALOX15, however, only IL-4 stimulation seems to drive ALOX15 expression to
levels higher than the basal expression of ALOX15B. Hence, ALOX15B may play a major role in human
atherosclerosis.
 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
There is compelling evidence for an anti-inﬂammatory effect of
12- and 15-lipoxygenases through the generation of lipid mediators
involved in the resolution of inﬂammation [1]. On the other hand,
there is compelling evidence for a pro-atherosclerotic effect
through the formation of oxLDL which accelerates foam cell
formation and through its role in signalling of angiotensin II
mediated mechanisms and vascular smooth muscle cell prolifera-
tion [1]. Hence, the 12/15-lipoxygenases seem to be two-faced
enzymes with an anti-inﬂammatory effect through lipid mediator
production, and a pro-inﬂammatory and atherogenic effect through
oxLDL formation and participation in signalling pathways [1].
Animal models of atherosclerosis did not solve the question of
whether the 12/15-lipoxygenase activity is pro- or anti-atherogenic
because different animal models showed contrasting results [2e7].
Monocyte speciﬁc 15-lipoxygenase expression in transgenic rabbits
reduced atherosclerosis and supported the anti-inﬂammatory role
of the 15-lipoxygenase [2,3]. Similarly, an extensive mouse
study applying several overexpressing and knockout mouse lines
showed an atheroprotective effect of the 15-lipoxygenase under
a normal diet [7]. However, conditional macrophage-speciﬁc and
general disruption of the mouse homolog 12-lipoxygenase gene
reduced atherosclerosis [4,5], while overexpression of human 15-
lipoxygenase in vascular endothelium enhanced atherosclerosis in
other mouse strains on a cholesterol rich diet [6]. The discrepancies
between the different animal models have been explained by the
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different positional selectivities of the mammalian 12- and 15-
lipoxygenase iso-enzymes which oxidize arachidonic acid at the
carbon atoms 12 and 15 and which have different expression
patterns, and by the composition of the food used in these animal
studies [1,8].
To investigate the role of the 12/15-lipoxygenases in human
atherosclerosis, genetic studies have been carried out which
investigated the association of the human ALOX15 gene with
coronary artery disease andmyocardial infarction [9e11]. Although
there is currently more support for a neutral or an atheroprotective
role of ALOX15 than for the contrary, these human genetic studies
did not consistently show an association of functional variants in
ALOX15 with clinical end points of atherosclerosis [12]. The lack of
consistent associations may be explained by the lack of power of
the studies due to the low frequency of the two functional poly-
morphisms [12]. However, another explanation may be redun-
dancy for the 12/15-lipoxygenase activity in human macrophages.
Recently a second 15-lipoxygenase isoform, ALOX15B, was detec-
ted in human atherosclerotic plaques [13,14]. Immunohistochem-
ical analyses showed abundant ALOX15B expression in
macrophage-rich areas of carotid lesions, and lipidomic analyses
demonstrated the presence of typical ALOX15B products in plaque
tissue [15].
These ﬁndings suggest that eventually more than one 12/15-
lipoxygenase isoform may play a role in human atherosclerosis.
Humans have two 12-lipoxygenases and two 15-lipoxygenases
which show different expression patterns, substrate speciﬁcities
and stereo-selective metabolism [1]. However, in cells involved in
atherosclerosis only the 12-lipoxygenase, ALOX12, and the two
15-lipoxygenases, ALOX15 and ALOX15B, seem to be expressed [15].
To identify the major 12/15-lipoxygenases in human macrophages
and to better understand their role in human atherosclerosis, we
investigated the basal and stimulated expression of these three
12/15-lipoxygenase isoforms ALOX12, ALOX15 and ALOX15B in
human primary macrophages.
2. Materials and methods
2.1. Material
IL-1b, INF-g, LPS, Poly I:C, TNF-a and TGF-b were purchased
from SigmaeAldrich (Buchs, Switzerland). IL-4, IL-13, IL-6 and the
human M-CSF were obtained from R&D Systems Europe Ltd.
(Abingdon, United Kingdom). The TLR9 ligand, CpG-
oligodeoxynucleotides (CpG) was synthesized by Microsynth (Bal-
gach, Switzerland). The TLR7 and TLR8 ligands 3M-001 rsp. 3M-002
were purchased from 3M Pharmaceuticals (St. Paul, Minnesota,
USA). ALOX15 antibody (Anti-15 Lipoxygenase 1, monoclonal
antibody) was ordered from Abcam (Cambridge, United Kingdom),
ALOX15B antibody (Anti-15-LOX form 2, polyclonal antibody) from
Oxford Biomedical Research (Oxford, United Kingdom) and the
b-actin antibody from SigmaeAldrich.
2.2. Preparation of human peripheral monocytes and cell culture
White blood cells from healthy volunteers were isolated from
buffy coat (Blutspendezentrum Zürich, Schlieren, Switzerland)
using Histopaque-1077 gradient (SigmaeAldrich). Peripheral
human monocytes were puriﬁed by capturing with anti-CD14
antibody coupled to MACS microbeads (Miltenyi Biotech, Ber-
gisch Gladbach, Germany). Monocytes were seeded with a density
of 0.7*106 cells/ml and were cultured for differentiation into
macrophages for 7 days at 37 C and 5% CO2 in RPMI-1640 (Sigmae
Aldrich) supplemented with 5% Fetal Calf Serum (Bioconcepts,
Allschwil, Switzerland), 5% Human AB Serum (SigmaeAldrich), 1%
Penicillin/Streptomycin (Invitrogen, Zug, Switzerland). For the
stimulation experiments with the set of cytokines, the cells were
starved for 24 h in RPMI-1640 (SigmaeAldrich) containing 1%
Penicillin/Streptomycin (Invitrogen) before they were cultured in
RPMI-1640 (SigmaeAldrich) supplemented with 5% Human AB
Serum (SigmaeAldrich), 1% Penicillin/Streptomycin (Invitrogen)
and the indicated cytokines for different time points. Monocytes
were differentiated to macrophages in the presence of M-CSF
(50 ng/ml) for western blot experiments with IL-4 and IL-13 stim-
ulation. For the protein experiment with LPS stimulation human
monocytes were differentiated without M-CSF stimulation. All
experiments were performed under normoxic conditions, unless
indicated. For hypoxic conditions, cells were incubated in a hypoxic
chamber at 0.2% O2 and 5% CO2 for the indicated times without
M-CSF stimulation.
2.3. Quantitative real-time PCR (qPCR)
Total amount of RNA was extracted using RNeasy Mini Kit
(Qiagen AG, Hombrechtikon, Switzerland) and the reverse tran-
scription reaction was performed with 0.5 mg RNA in a 20 ml reac-
tion using random primer (Invitrogen) with the Superscript III
Reverse Transcriptase (Invitrogen) according to the manufacturer’s
instructions. The qPCR reaction was done on a LightCycler 480
system (Roche Diagnostics, Rotkreuz, Switzerland) utilizing a hot-
start SYBR green method with the following parameters: preheat-
ing for 10 min at 95 C, followed by 40 cycles of denaturation for
10 s at 95 C, annealing for 10 s at 60 C and extension for 10 s at
72 C. The quantiﬁcation PCR included 50 ng cDNA, 0.5 mM primers
forward and reverse and 5 SYBR green master mix (Roche Diag-
nostics). The primers were designed with the OLIGO 6.0 software
(Molecular Biology Insights, Inc., Cascade, USA) and the sequences
are listed in Table 1. To quantify the 2 variants of ALOX15B, the
primer pair ALOX15B-exon 9 was created with the upper primer
located in exon 9 to detect the canonical isoform ALOX15B only. To
quantify ALOX15Bsv-a, the canonical ALOX15B mRNA was sub-
tracted from the total ALOX15B mRNA obtained with the primer
pair ALOX15B, which detects both variants, ALOX15B and
ALOX15Bsv-a. Calculation of the absolute copy number was done
using individual standard curves and the following equation: copy
Table 1
Sequences of qPCR primers.
Gene Forward primer Reverse primer
ALOX12 NM_000697.2 50AGTTCCTCAATGGTGCCAAC30 50GCAGCCAGGTATTGCTTCTC30
ALOX15 NM_001140.3 50CTTCAAGCTTATAATTCCCCAC30 50GATTCCTTCCACATACCGATAG30
ALOX15B NM_001141.2 50CTACAGGCTGGCTCTGCTTT30 50GGATCAGGACAGGGTTGAGA30
ALOX15B-exon 9 NM_001141.2 50GACAAGTGGGACTGGTTGCT30 50TTGATGTGCAGGGTGTATCG30
GAPDH NM_002046.3 50CCCATGTTCGTCATGGGTGT30 50TGGTCATGAGTCCTTCCACGATA30
L28 NM_001136134.1 50GCAATTCCTTCCGCTACAAC30 50TGTTCTTGCGGATCATGTGT30
IL-10 NM_000572 50GATCCAGTTTTACCTGGAGGAG30 50CCTGAGGGTCTTCAGGTTCTC30
TNF-a NM_000594 50GAGTGACAAGCCTGTAGCCCATGTTGTAGCA30 50GGCAATGATGATCCCAAAGTAGACCTGCCCAGACT30
IL-1b NM_000576 50TACCTGTCCTGCGTGTTGAA30 50TCTTTGGGTAATTTTTGGGATCT30
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number per ml ¼ amount of original PCR product (ng)*6.022*1023/
number of basepairs of the PCR product*650*109*dilution factor.
2.4. Western blot analysis
Macrophages cultured in cell culture dishes were washed with
phosphate buffer saline solution (GIBCO PBS, Invitrogen) and lysed
using ProteoJet Mammalian Cell Lysis Reagent (Fermentas,
St.Leon-Rot, Germany). Protein concentrations were determined
using the ND-1000 Spectrometer Nanodrop (NanoDrop Technolo-
gies, Inc., Wilmington, USA). Protein samples were denatured using
Laemmli buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol,
0.004% bromophenol blue, 0.125MTris HCI) and electrophoretically
separated on a 4e12% BiseTris Gel NUPAGE SDS gel (Invitrogen) and
transferred to nitrocellulose membranes (Protran, 0.45 mm, What-
man SwitzerlandGmbH, Bottmingen, Switzerland). Themembranes
were blocked with 5% bovine serum albumin (BSA, SigmaeAldrich)
in Tris-buffered saline solution containing 0.2% Tween 20 (TBST)
(TBS, 0.2M Trisbase,1.5MNaCl, pH 7.6) for 3 h at room temperature
(RT). Membranes were then incubated overnight at 4 C with anti-
alox15 antibody (1:2000) or anti-alox15b antibody (1:2000). After
washing in TBST, the blots were blocked for 1 h in a 5% BSA-TBST
solution and incubated with horseradish peroxidase (HRP)-conju-
gated secondary antibody for 2 h at RT (1:10’000, anti-rabbit IgG for
alox15b and anti-mouse IgG for alox15 detection, GE Healthcare,
Glattbrugg, Switzerland). Following the rinse in TBST the blots were
developed using the enhanced chemiluminescence (ECL) kit (GE
Healthcare) and exposed to UltraCruz Autoradiography Film
(Santa Cruz Biotechnology, Heidelberg, Germany). The blots were
incubated in RestoreWestern Blot Stripping Buffer (Fisher Scientiﬁc
AG, Wohlen, Switzerland) for 15 min at RT and reprobed with
antibodies for b-actin (1:10,000). Autoradiographic ﬁlms were
scanned and quantitative analysis of detected peptides was per-
formed by densitometry using the quantity one software (Bio-Rad
Laboratories, Hemel Hempstead, United Kingdom).
2.5. FACS analysis
FACS analysis was performed using a monoclonal PE-labeled
anti-human CD80, a monoclonal FITC-labeled anti-human CD206
and an IgG1K isotype control (BD Biosciences, San Jose, California
USA). Brieﬂy, cells were resuspended in PBS containing 2.5% FCS
(Bioconcepts) and incubated in the dark for 30 min at 4 C before
analysis was carried out on a FACS Calibur Analyzer (BD Biosci-
ences, San Jose, California USA).
2.6. Characterization of macrophages
To conﬁrm the polarization of the resting macrophages into the
M1 (LPS) and M2 (IL-4, IL-13) subtypes following stimulation, we
measured the expression of different markers characteristic for the
two subpopulations. LPS stimulation increased the mRNA expres-
sion of the pro-inﬂammatory cytokines IL-1b and TNF-a and the
cell surface expression of CD80 (Supplementary Fig. 1). IL-4 and IL-
13 stimulation increased the mRNA expression of the anti-
inﬂammatory cytokine IL-10, reduced the mRNA of the pro-
inﬂammatory IL-1b and TNF-a, and increased the surface marker
CD206 (Supplementary Figs. 2 and 3).
2.7. Statistical analysis
Statistical analysis was done using the software excel (t-test)
(Microsoft, Wallisellen, Switzerland) or graphprism 4 (ADNOVA)
(GraphPad Prism Software, Inc, La Jolla, USA). Differences between
individual groups were calculated using two-tailed unpaired
students t-test, while one way ADNOVA with the Dunnett’s post
test was used for time course experiments. Results are shown as
mean SD and a p-value of <0.05 was considered signiﬁcant.
3. Results
3.1. mRNA expression of the 12/15-lipoxygenases in the time course
of monocyte to macrophage differentiation
To investigate the expression of the 3 different 12/15-
lipoxygenases, ALOX12, ALOX15 and ALOX15B, in monocytes and
macrophages, the absolute copy number of the different mRNAs
was measured in a time course experiment from day 0 to day 7
during the differentiation of monocytes to macrophages. As shown
in Fig. 1, the expression of the ALOX15B mRNA increased during the
time of differentiation while ALOX12 and ALOX15 expression
stayed at the same low level. These results indicate that ALOX15B is
expressed in non-stimulated human resident macrophages and
that it represents the only 12/15-lipoxygenase in these cells (Fig. 1).
3.2. Expression of ALOX12, ALOX15 and ALOX15B mRNA after
stimulation of human macrophages with pro- and anti-
inﬂammatory stimuli
To investigate the regulation of the 3 different 12/15-
lipoxygenases, human macrophages were stimulated with
different pro- and anti-inﬂammatory cytokines, TLR agonists or
incubated under hypoxic conditions for 24 h, and the relativemRNA
expression was measured by qPCR. None of the stimuli had an
effect on ALOX12 mRNA expression (Fig. 2A). In contrast, the anti-
inﬂammatory cytokines IL-4 and IL-13 increased ALOX15 mRNA
expression in human macrophages (Fig. 2B), similar to the previ-
ously described increase in human monocytes [16]. Intriguingly,
ALOX15BmRNA expressionwas stimulated by IL-4, IL-13 and by the
pro-inﬂammatory Toll-like Receptor 4 (TLR4) agonist LPS, while the
pro-inﬂammatory cytokine IL-6 reduced ALOX15B mRNA expres-
sion. In addition, we corroborated previous results showing that
ALOX15B expression increases upon hypoxic treatment of macro-
phages (Fig. 2C) [13]. No stimulation of any of the 12/15-
lipoxygenases was observed with IL-1b, TNF-a, TGF-b, and with
the agonists for TLR3 (Poly I:C), TLR7 (3M-001), TLR8 (3M-002), and
TLR9 (CpG).
Since four ALOX15B mRNA isoforms (ALOX15Bsv-a/b/c) have
been observed in prostate epithelial cells [17], we ﬁrst investigated
the presence of these isoforms in monocytes and macrophages. As
Fig. 1. Absolute copy number of the ALOX12 (dotted), ALOX15 (dashed) and ALOX15B
(black) mRNA in the time course of the differentiation of monocytes to macrophages
from day 0 to day 7. Bars indicate the mean of 3 independent experiments. *p < 0.05,
**p < 0.01.
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previously observed [13], human macrophages express the
canonical isoform and the splice variant ALOX15Bsv-a, which most
likely will translate an inactive protein [13]. To investigate whether
the relative abundance of these isoforms is altered in macrophages
by the stimuli applied, we quantiﬁed the two isoforms by qPCR. As
shown in Fig. 2C, none of the stimuli altered the splicing pattern of
ALOX15B suggesting that differential splicing was not regulated in
macrophages under the investigated stimulations.
To estimate which of the two 15-lipoxygenases, ALOX15 and
ALOX15B is the major 12/15-lipoxygenase in human M2 macro-
phages, we compared the absolute copy number of the ALOX15 and
the ALOX15B mRNAs following IL-4 and IL-13 stimulation. As
shown in Fig. 3 the stimulated expression of ALOX15B is higher in
M2 macrophages than ALOX15 expression after stimulation with
these two cytokines. Interestingly, only the stimulation of
macrophages with IL-4 increased the ALOX15 mRNA expression to
levels higher than ALOX15B expression in untreated cells (Fig. 3).
These results indicate that ALOX15B is also a major source of 12/15-
lipoxygenase activity in stimulated macrophages and that the
mRNA levels are comparable to or even higher than the mRNA
levels of ALOX15 in such M2 macrophages.
3.3. ALOX15 and ALOX15B protein expression in a time course
experiment with IL-4, IL-13, LPS and hypoxia over 3 days
To test the long term effect of IL-4, IL-13, LPS and hypoxia
stimulation on the expression of ALOX15 and ALOX15B, human
macrophages were stimulated for 24, 48 and 72 h. IL-4 increased
ALOX15 mRNA expression with a signiﬁcant peak at 48 h (Fig. 4A,
black) and IL-13 enhanced the mRNA expression gradually over 3
days with a peak at 72 h (Fig. 4A, dotted). Stimulation of ALOX15
expression by IL-4 could be conﬁrmed on the protein level by
western blot analysis (Fig. 4B, black) whereas stimulation with IL-
13 only slightly induced protein expression (Fig. 4B, dotted).
In the same time course experiments, ALOX15B mRNA expres-
sion gradually increased over 3 days following IL-4, IL-13 and LPS
stimulation (Fig. 5A). This rise in ALOX15B was also observed on the
protein level following IL-4 and LPS stimulation. Stimulation by IL-4
and LPS supported translation of ALOX15B protein expression in
a cumulative way (Fig. 5B, black and dashed) while the stimulation
by IL-13 was not translated into protein (Fig. 5B, dotted). To
investigate the ALOX15B expression under hypoxia in a time
course, human macrophages were incubated for 24, 48 and 72 h
under hypoxic conditions. The ALOX15B mRNA showed an increase
after 24 h and peaked at 72 h (Fig. 5A, white) while the protein
levels peaked after 48 h (Fig. 5B, white).
4. Discussion
In this study we demonstrate that ALOX15B is the only 12/15-
lipoxygenase expressed in human resident and hypoxic macro-
phages and that polarization with LPS further increases ALOX15B
expression in M1 macrophages. Only in macrophages stimulated
with IL-4, ALOX15B and ALOX15 are expressed, indicating that in
such M2 macrophages both isoforms are responsible for the 15-
lipoxygenase activity. These results emphasize that in addition to
hypoxic resident macrophages and M2 macrophages, a certain set
of human M1 macrophages will also express 15-lipoxygenase
activity.
In addition to the differentiation of monocytes into resident
macrophages, macrophages can be polarized into at least two
subpopulations, identiﬁed as M1 and M2 macrophages, analogous
to the well characterized Th1 and Th2 subpopulations of T-helper
Fig. 2. Relative mRNA expression of ALOX12, ALOX15 and ALOX15B after stimulation of
human macrophages with different stimuli for 24 h (IL-4 10 ng/ml, IL-13 10 ng/ml, TGF-
b 1 ng/ml, IL-1b 1 ng/ml, IL-6 10 ng/ml, INF-y 50 ng/ml, TNF-a 1 ng/ml, CpG 100 ng/ml,
LPS 100 ng/ml, Poly I:C 1 ng/ml, 3M001 3 mM, 3M002 3 mM). The values were
normalized for GAPDH and L28 mRNA expression for the cytokines and TLR agonists,
and for hypoxia, respectively. A: ALOX12, B: ALOX15, C: ALOX15B canonical isoform
(dotted) and both variants (black), ALOX15B and ALOX15Bsv-a. Bars indicate the mean
of 3 independent experiments as fold induction of control. *p < 0.05, **p < 0.01.
Fig. 3. Absolute mRNA expression of ALOX15 (dashed) and ALOX15B (black) after
stimulation of human macrophages with IL-4 and IL-13 for 24 h (IL-4 10 ng/ml, IL-13
10 ng/ml). Bars indicate the mean of 3 independent experiments. *p < 0.05, **p < 0.01.
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cells [18]. Stimulation of macrophages with INF-g (released by Th1
cells) and LPSwill lead to the classically activated pro-inﬂammatory
M1 macrophages, which secrete IL-1b, IL-15, IL-18, TNF-a and IL-12
[19]. Such M1 cells are characterized by enhanced endocytic func-
tions and enhanced ability to kill intracellular pathogens. In
contrast, stimulation of macrophages with IL-4, IL-10 (both
released by Th2 cells), IL-13, glucocorticoids and TGF-b will lead to
an anti-phlogistic macrophage phenotype M2 involved in tissue
regeneration and homeostasis [18,19]. Both types of activated
macrophages have been detected in atherosclerotic plaques,
although the role of the differently activated macrophages in
human atherosclerosis has not been fully elucidated [20,21]. Clas-
sically activated M1 macrophages predominate in the lipid core of
human carotid atherosclerotic lesions, whereas anti-phlogistic M2
macrophages prevail in the shoulder region as well as in the
periphery of the plaque [22]. There is some indication from the
secreted cytokine proﬁle of polarized macrophages that classically
activated M1 macrophages are pro-atherogenic, while the anti-
phlogistic M2 macrophages are atheroprotective [23].
The surprising ﬁnding of our study is that human M1 macro-
phages stimulated by LPS express ALOX15B to high levels. So far 12/
15-lipoxygenase activity was only reported for IL-4 stimulated anti-
phlogistic M2 macrophages [9] but not for the classically activated
M1 macrophages. Our data suggest that such M1 macrophages will
speciﬁcally express ALOX15B while the M2 macrophages express
both ALOX15 and ALO15B isoforms to similar levels. From an
enzymatic point of view there are differences between the two 15-
lipoxygenases considering substrate preference and positional
speciﬁcity, which may even inﬂuence the role of the two iso-
Fig. 4. mRNA and protein expression of ALOX15 after stimulation with IL-4 and IL-13
for 24, 48 and 72 h (IL-4 10 ng/ml, IL-13 10 ng/ml). A: mRNA expression following IL-4
(black) and IL-13 (dotted) stimulation; B: protein expression following IL-4 (black) and
IL-13 (dotted) stimulation. C: representative western blot used for the densitometric
analysis following IL-4 and IL-13 stimulation. Bars indicate the mean of 3 independent
experiments as fold induction of control. *p < 0.05, **p < 0.01.
Fig. 5. Expression of ALOX15B after stimulation with cytokines, LPS and hypoxia for 24,
48 and 72 h (IL-4 10 ng/ml, IL-13 10 ng/ml, LPS 100 ng/ml, hypoxic conditions (0.2% O2,
5% CO2)). A: mRNA expression following IL-4 (black), IL-13 (dotted), LPS (dashed), and
hypoxia (white) stimulation. B: protein expression following IL-4 (black), IL-13
(dotted), LPS (dashed) and hypoxia (white) stimulation. C: representative western
blot used for the densitometric analysis following IL-4, IL-13, LPS and hypoxia stim-
ulation. *p < 0.05, **p < 0.01.
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enzymes in atherosclerosis. In general, ALOX15B seems to prefer-
entially oxygenate arachidonic acid leading to the formation of the
anti-inﬂammatory lipid mediators while it metabolizes linoleic
acid to 13(S)-hydro(per)oxy-octadecadienoic acid (13-HpODE)
involved in LDL-oxidation to a lesser extend than ALOX15 [24,25].
In addition, ALOX15B was reported to be enzymatically active for
longer periods, in contrast to ALOX15 for which rapid suicide
inactivation has been observed [25,26]. These substrate preferences
and the lack of suicide inactivation may suggest an even more anti-
inﬂammatory metabolite proﬁle for human ALOX15B than for
ALOX15.
ALOX15 expression was co-localized with LDL to macrophage-
rich areas in early atherosclerotic lesions in humans [27e30] and
speciﬁc ALOX15 products were observed in these lesions [29,31].
However, conﬂicting results have been observed about the
temporal and regiospeciﬁc expression patterns of the peroxidizing
ALOX15 enzyme in humans. ALOX15 protein and mRNA were
detected inmacrophage-rich areas of human fatty streaks as well as
in more advanced human atherosclerotic lesions by in situ
hybridization [31]. The expression of ALOX15 in early atheroscle-
rotic lesions was corroborated by measuring the speciﬁc ALOX15
metabolite 13-HpODE in arterial sections [29,32]. This study
showed that the speciﬁc ALOX15 metabolite was abundant in early
human atherosclerotic lesions but was not in later stages of plaque
development, where non-enzymatic lipid peroxidation surpassed
the ALOX15 dependent lipid peroxidation [29,32]. Therefore,
ALOX15may play a role in the initiation of atherosclerosis but not in
later stages of atherogenesis. However, the expression of ALOX15 in
early atherosclerotic development was later questioned by inves-
tigations which only detected minor human ALOX15 mRNA and
protein in atherosclerotic lesions and found no co-localization of
ALOX15 with macrophages [15,33]. Instead, ALOX15B expression
was detected in human carotid atherosclerotic plaques and
immunohistochemical analysis showed abundant ALOX15B in
macrophages-rich areas of carotid lesions [13e15]. In these studies
hypoxiawas shown to regulate ALOX15BmRNA expression through
a HIF-1 alpha mediated mechanism [14]. Our ﬁndings corroborate
the upregulation of ALOX15B by hypoxia and expand our knowl-
edge on the regulation of ALOX15B in macrophages, showing that
the enzyme is not only regulated by HIF-1 alpha but also by IL-4 and
LPS. Hence, a larger set of macrophages will have 15-lipoxygenase
activity from ALOX15B expression including certain sets of M1
and M2 macrophages.
The preferential expression of ALOX15B in human macrophages
may explain why human genetic studies investigating the associa-
tion of ALOX15 with cardiovascular disease did not show consistent
results. Two rare functional polymorphisms have been character-
ized in the ALOX15 gene,which leads to increased (c.292C>T) [34]
and reduced (T560M) [10] enzyme activity, respectively. While the
activating c. 292C>T polymorphism showed a trend towards an
atheroprotective effect in a small caseecontrol study for coronary
artery disease, the inactivating T560M polymorphism was associ-
atedwith a signiﬁcantly increased risk for coronary artery disease in
the ADVANCE study, indicating that ALOX15 may be anti-
inﬂammatory and anti-atherogenic in humans [9,10]. However,
corroboration of such an atheroprotective effect of the ALOX15 gene
failed in a larger caseecontrol study on myocardial infarction
possibly because of the low frequency of the T560M polymorphism
[11]. So far all large Caucasian study samples investigating the
association of the inactivating polymorphism (T560M) in ALOX15
showed a similar risk increase which was, however, not signiﬁcant
in two of the studies [10,11]. In light of our results which emphasize
that ALOX15B is the major 12/15-lipoxygenase in human macro-
phages, further research on the role of the ALOX15B gene in human
atherosclerosis would be warranted.
In summary, we show that ALOX15B is the mainly expressed
12/15-lipoxygenase in human macrophages and that its expression
is induced by IL-4, LPS and hypoxia. Interestingly, IL-4 and IL-13 also
increase the expression of ALOX15 but only IL-4 stimulation seems
to drive ALOX15 expression to levels higher than the basal
expression of ALOX15B. These expression studies suggest that
ALOX15B may play a more important role in human atherosclerosis
than ALOX15.
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6.3 Unpublished data:  
6.3.1Transfection methods tested for RAW 264.7 cells. 
RAW264.7 cells are known to be hard to transfect. Several transfection methods were 
tested to compare their efficiency on RAW264.7 cells.  
 
I.- HiPerFect transfection reagent (Qiagen): 
1. Cells were seeded one day before transfection in six well dishes and incubated at a 
density of approx. 2 x 106/mL and grown in DMEM (Sigma). Media were supplemented 
with 10% fetal calf serum (FCS) and antibiotics (50 IU/ml penicillin and 100 μg/ml 
streptomycin; Gibco-BRL). Cells were incubated under normal growth conditions (37°C 
and 5% CO2). 
2. siRNA  was diluted to a final concentration of 50nM in culture medium without serum. 
3. 40 μl of HiPerFect transfection reagent was added to culture medium without serum, 
and then added to the diluted siRNA. 
4. Samples were incubated for 10 min at room temperature (15–25°C) to allow the 
formation of transfection complexes. 
5. Complexes were added drop-wise onto the cells. Plates were gently swirled to ensure 
uniform distribution of the transfection complexes. 
6. Cells were incubated with the transfection complexes under their normal growth 
conditions. 
7. Culture medium containing serum and antibiotics was changed the following day.  
Cells were incubated until analysis of gene silencing (24 h after transfection). 
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II.- Electroporation of Cells (BioRad GenePulserII): 
1. Cells were seeded one day before transfection in six well dishes and incubated at a 
density of approx. 2 x 106/mL and grown in DMEM (Sigma). Media were supplemented 
with 10% fetal calf serum (FCS) and antibiotics (50 IU/ml penicillin and 100 μg/ml 
streptomycin; Gibco-BRL). Cells were incubated under normal growth conditions (37°C 
and 5% CO2). 
2. Cells were collected, washed once with PBS, counted, resuspended at 2 to 10 x 106 
cells/350 μl medium without FCS. 
3. Electroporation cuvettes were sterilized with EtOH in the laminar flow work bench 
4. siRNA  was diluted to a final concentration of 50 nM in culture medium without serum. 
5. siRNA and 350 μl of cells were added, gently shaken, electroporated at  1000 μF/250 
V/∞Ω (τ at 25 msec) and resuspended in 10 ml medium containing FCS. 
7. Culture medium containing serum and antibiotics was changed the following day.  
Cells were incubated until analysis of gene silencing (24 h after transfection). 
 
III.- Metafectene (Biontex Laboratories): 
1. Cells were seeded one day before transfection in six well dishes and incubated at a 
density of approx. 2 x 106/mL and grown in DMEM (Sigma). Media were supplemented 
with 10% fetal calf serum (FCS) and antibiotics (50 IU/ml penicillin and 100 μg/ml 
streptomycin; Gibco-BRL). Cells were incubated under normal growth conditions (37°C 
and 5% CO2). 
2. siRNA  was diluted to a final concentration of 50 nM in culture medium without serum. 
3. 40 μl of Metafectene transfection  reagent was added to culture medium without 
serum, and then added to the diluted siRNA. 
4. Samples were incubated for 20 min at room temperature (15–25°C) to allow the 
formation of transfection complexes. 
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5. Complexes were added drop-wise onto the cells. Plates were gently swirled to ensure 
uniform distribution of the transfection complexes. 
6. Cells were incubated with the transfection complexes under their normal growth 
conditions for. 
7. Culture medium containing serum and antibiotics was changed the following day.  
Cells were incubated until analysis of gene silencing (24 h after transfection). 
 
IV.- Amaxa electroporation (Amaxa Biosystems): 
1. Cells were seeded one day before transfection in six well dishes and incubated at a 
density of approx. 4 x 106/mL and grown in DMEM (Sigma). Media were supplemented 
with 10% fetal calf serum (FCS) and antibiotics (50 IU/ml penicillin and 100 μg/ml 
streptomycin; Gibco-BRL). Cells were incubated under normal growth conditions (37°C 
and 5% CO2). 
2. Cells were centrifuged at 90 x g for 10 minutes. 
3. After carefully removing the supernatant, the cell pellet was resuspended in 100 μL 
mouse macrophage nucleofector solution with supplement (Amaxa Biosystems) 
4. siRNA (2 μg) or endotoxin-free pmaxGFP plasmid DNA (Amaxa Biosystems) as 
transfection control was added and the cells electroporated (Amaxa Nucleofector II, 
program D-032).  
5. Immediately afterwards, cells were diluted in 0.2 mL of DMEM and transferred to 10 
cm cell culture dishes. 
6. Cells were incubated with the transfection complexes under their normal growth 
conditions. 
7. Culture medium containing serum and antibiotics was changed the following day.  
Cells were incubated until analysis of gene silencing (24 h after transfection). 
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V.- Lipofectamine (Invitrogen): 
1. Cells were seeded one day before transfection in six well dishes and incubated at a 
density of approx. 2 x 106/mL and grown in DMEM (Sigma). Media were supplemented 
with 10% fetal calf serum (FCS) and antibiotics (50 IU/ml penicillin and 100 μg/ml 
streptomycin; Gibco-BRL). Cells were incubated under normal growth conditions (37°C 
and 5% CO2). 
2. siRNA  was diluted to a final concentration of 50 nM in OptiMEM®. 
3. 40 μl of Lipofectamine transfection reagent was added to 100 μL OptiMEM®, 
4. Samples were incubated for 10 minutes, mixed and incubated for 20 min at room 
temperature (15–25°C) to allow the formation of transfection complexes. 
5. Complexes were added drop-wise onto the cells. Plates were gently swirled to ensure 
uniform distribution of the transfection complexes. 
6. Cells were incubated with the transfection complexes under their normal growth 
conditions. 
7. Culture medium containing serum and antibiotics was changed the following day.  
Cells were incubated until analysis of gene silencing (24 h after transfection). 
 
VI.- Polyethylenimine (PEI) 
1. PEI stock solution were prepared: 1 mg/ml PEI in sterile H2O with 18 μl 1 M HCI/ml, 
filtered and frozen at -20°C.  
2. Cells were seeded one day before transfection in six well dishes and incubated at a 
density of approx. 2 x 106/mL and grown in DMEM (Sigma). Media were supplemented 
with 10% fetal calf serum (FCS) and antibiotics (50 IU/ml penicillin and 100 μg/ml 
streptomycin; Gibco-BRL). Cells were incubated under normal growth conditions (37°C 
and 5% CO2). 
3. siRNA  was diluted to a final concentration of 50 nM in culture medium without serum. 
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4. 40 μl of PEI was added to culture medium without serum and then added to the 
diluted siRNA.  
5. Samples were incubated for 30 min at room temperature (15–25°C) to allow the 
formation of transfection complexes. 
6. Complexes were added drop-wise onto the cells. Plates were gently swirled to ensure 
uniform distribution of the transfection complexes. 
7. Culture medium containing serum and antibiotics was changed the following day.  
Cells were incubated until analysis of gene silencing (24 h after transfection). 
 
VII.- Lullaby transfection reagent (OZ Biosciences): 
1. Cells were seeded one day before transfection in six well dishes and incubated at a 
density of approx. 2 x 106/mL and grown in DMEM (Sigma). Media were supplemented 
with 10% fetal calf serum (FCS) and antibiotics (50 IU/ml penicillin and 100 μg/ml 
streptomycin; Gibco-BRL). Cells were incubated under normal growth conditions (37°C 
and 5% CO2). 
2. siRNA  was diluted to a final concentration of 50 nM in culture medium without serum. 
3. 40 μl of Lullaby transfection reagent was added to culture medium without serum, and 
then added to the diluted siRNA. 
4. Samples were incubated for 15 min at room temperature (15–25°C) to allow the 
formation of transfection complexes. 
5. Complexes were added drop-wise onto the cells. Plates were gently swirled to ensure 
uniform distribution of the transfection complexes. 
6. Cells were incubated with the transfection complexes under their normal growth 
conditions for 6 h. 
7. Culture medium containing serum and antibiotics was changed the following day.  
Cells were incubated until analysis of gene silencing (24 h after transfection). 
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VII. Lentivirus Production using Invitrogen packaging plasmids. 
Production of lentivirus-pseudotyped particles 
1. HEK 293T cells were plated at a density of  7×106  cells per 75 cm2 culture flask 24 
hours before  transfection. At least one flask was required per virus. 
2. Each plate was transfected with the following transfection mix according to the PEI 
transfection protocol: 
Transfer vector (e.g. pLKO.1, pLenti4 or 6) 3.0 μg 
pLP1 4.2 μg 
pLP2 2.0 μg 
pVSV-G 2.8 μg 
total 12.0 μg 
 
3. Medium was replaced the day after transfection with 15 ml fresh media containing 
serum and antibiotics. Transfection efficiency was visualized by fluorescence 
microscopy  24 hours post transfection with a pLenti6-EGFP control. 
 
4. Cell culture supernatant was collected  48-72 hours post transfection.  
 
5. Cell culture supernatant was spinned down to remove cell debris, then filtered through  
a 0.45 μm filter. Viral stocks were stored at 4°C. 
 
Infection using lentivirus-pseudotyped particles  
 
1.Cells were plated the day before infection to reach approximately 50% confluency. 
 
2.A 1:1 mixture of viral stock and fresh media was applied (containing 12 μg/ml 
polybrene to final concentration of 6 μg/ml). 
 
3.Media was replaced with complete media the day after infection. 
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4.Selection of the infected cells was started 72 hours after infection using respective 
antibiotics (puromycin).  
 
6.3.2 Results of transfection tests 
Figure 1  shows transfection efficiencies measured by pmaxGFP reporter control (From 
amaxa kit-lonza) and Western blotting of some of the methods tested. 
           
 
 
Fig. 1 Metafectene, Amaxa electroporation, HiPerfect and Lipofectamine transfection 
efficiencies measured by western blotting and fluorescent microscopy.  
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Amaxa electroporation  showed a better transfection efficiency for siRNA against HIF-
1α compared with the other methods. We observed a slight decrease in HIF-
1α expression levels compared with the siControl. However, HIF-1α levels was still too 
high. 
 
 
Fig.2 HIF-1α silencing by AMAXA electroporation.   
 
 
The highest efficiency for transfecting RAW264.7 was obtained by lentiviral infection, as 
seen by the decrease in HIF-1α expression levels by western blotting (Figure 3). 
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Fig. 3 Immunoblotting of RAW264.7 cells following lentivira transfection of shRNA 
against HIF-1α. 
 
In conclusion, the best efficient method for transfecting RAW264.7 cells and decreasing 
HIF-1α levels was obtained using lentiviral approaches with shHIF-1α plasmids. 
However, we were not able to maintain stable transfections with the selection antibiotic. 
RAW264.7 cells died  two days after infection.  
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7. Discussion 
Atherosclerosis is the leading cause of mortality worldwide. Despite that  
increasing research is shedding light into the biochemical and cellular mechanisms of 
atherosclerosis, further studies of the processes that lead to the progression of arterial 
plaques are  still needed for the development of future therapies.  
Atherosclerotic plaques contain metabolically active cells whose distances from a 
blood supply exceed the 100—200-μm diffusion limit for oxygen [1], but still the role of 
hypoxia in atherosclerosis is not yet fully explored. People exposed to hypoxia in 
obstructive sleep apnea show increased narrowing of their coronary arteries and 
increased risk of cardiovascular diseases [2]. Furthermore, chronic intermittent hypoxia 
has been shown to increase atherogenesis in mice [3]. 
Hypoxic areas in atherosclerotic plaques have been found in humans and in 
animal models as small as the rabbit, however the role of hypoxia in mouse 
atherosclerosis has been controversial. The size of mouse plaques is often within the 
diffusion distance for oxygen to penetrate from the lumen or the vasa vasorum. 
Nevertheless, Parathath and coworkers supported  the existence of hypoxia in murine 
plaques by demonstrating the presence of HIF-1α and an increase in the expression of 
HIF-1α targets. Furthermore, their results showed that hypoxia had a major effect on 
macrophage lipid metabolism and that HIF-1α promotes changes that would favor foam 
cell formation [4]. 
Foam cells, an important hallmark of atherogenesis, are likely to be exposed to 
hypoxic conditions because of the decreased oxygen diffusion and increased demand in 
the inner core of the plaque.  The lipids in macrophages include cholesteryl esters and 
triglycerids which are stored in lipid droplets within the cytosol. Their accumulation is 
mainly due to the uptake of modified lipoproteins, such as oxLDL and acLDL. Hypoxia 
has been previously reported as responsible for lipid accumulation in macrophages even 
in the absence of lipoproteins [5]. Furthermore, Glut3 it has recently been proposed a 
downstream target of HIF-1α for de novo lipogenesis in hypoxia-induced lipid loading of 
human macrophages [6]. Finally, fatty acid synthase is upregulated by hypoxia via Akt 
and sterol regulatory element binding protein-1 [7]. 
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  In this study we showed that both lipid content and oxLDL uptake were 
increasd following exposure of RAW264.7 to hypoxia. We report a differential 
modulation of SRA, CD36 and Lox-1 scavenger receptors involved in lipid uptake 
under this condition, highlighting the role of Lox-1 in atherogenesis.  
 
SRA decreased its mRNA and protein expression following hypoxic exposure 
in macrophages, while Lox-1 was upregulated at mRNA and protein levels, 
suggesting a compensatory mechanism under this condition. SRA protein regulation 
was further studied by the pan-PHD inhibitor DMOG which leads to the stabilization of 
HIF-1α under normoxic conditions. While HIF-1α protein levels were induced by both 
hypoxia and DMOG, SRA mRNA  and protein levels were reduced in RAW264.7 
cells. This hypoxic SRA reduction persisted for 24 hours of 0.5% or 1% oxygen but 
not beyond: SRA levels partially recovered after 48 hours hypoxia. Since HIF-1α 
levels were also reduced after 48 hours hypoxia, these data support an involvement 
of HIF-1α in SRA repression. 
 
Previous studies showed that HIF-1α protein levels were decreased under 
chronic hypoxia in MCF7 breast cancer cells, while HIF-2α protein levels were 
increased [8]. The abrogation of SRA decrease under a long exposure time to low 
oxygen suggests that this receptor can have an atheroprotective role at the early 
stage of the disease initially reducing foam cell formation. HIF-1α might play a role, 
either directly or indirectly, in SRA protein reduction under hypoxic conditions. After 
treatment with different low oxygen concentrations there was, as expected, an 
increase in HIF-1α protein levels, and a strong decrease in the expression of the SRA 
protein, suggesting that the effect is not affected by different low oxygen 
concentrations. CoCl2 and DMOG experiments revealed the involvement of PHD2 in 
the hypoxic inhibition of the scavenger receptor A, but not in CD36 decrease. Lox-1 
increase under hypoxia was clearly affected by DMOG exposure. Further studies are 
required to investigate the mechanism by which hypoxia is repressing SRA 
expression and upregulating Lox-1, through a direct or indirect HIF or PHD 
participation.  
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  Regarding CD36, the contradictory results obtained by western blotting and 
flow cytometry suggest a relocalization of this receptor following hypoxia. There have 
been recent publications reporting modulation of scavenger receptors involved in lipid 
uptake after low oxygen treatments.  In line with our results, SRA protein expression 
levels were shown to be inhibited by 1% of hypoxia and CoCl2 in RAW264.7 cells [9], 
while CD36 was shown to be increased under low oxygen concentrations in human 
dermal microvascular endothelial cells, human retinal pigment epithelial and 
pulmonary artery smooth muscle cells [10]. On the other hand previous studies 
reported a decrease in CD36 expression following exposure of adipocytes to hypoxia 
following hypoxia in cardiac myocytes [11], which can explain the differences we 
observed in CD36 hypoxic regulation with flow cytometry and western blotting. 
 
To the best of our knowledge, our study is the first one to demonstrate the 
importance of hypoxia induced Lox-1 for lipid uptake in macrophages. Hypoxia-
reoxygenation of cardiomyocytes has been reported to induce Lox-1 [12], but there 
are no other previous studies on the effect of hypoxia on Lox-1 expression. Lox-1, 
was first identified as a scavenger receptor for binding and uptake of oxLDL in 
endothelial cells, and it has been shown that Lox-1 plays important roles in pro-
inflammatory signaling and atherogenesis [13]. A cross-talk between hypoxia and 
inflammation has been further supported by the finding that both TNFα and NF-κB 
upregulate Lox-1 expression [14].  
 
 We found Lox-1 to be required for uptake of oxLDL under hypoxic conditions 
However, hypoxia only slightly stimulated the uptake of acLDL which was not affected 
by treatment with a blocking anti-Lox-1 antibody. These observations suggest that 
Lox-1 mediates mainly to the uptake of LDL oxidatively modified by an inflammatory 
milieu. In fact, we found a co-localization of TNFα and Lox-1 in the inner core of 
human advanced coronary plaques where the lowest tissue oxygenation could be 
expected. Bioinformatic analysis identified a putative HRE in the Lox-1 promoter at 
position -114 (data not shown) which might mediate the HIF effect. 
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Our study sheds light on the role of Lox-1 as an important player of 
atherogenesis, increasing lipid content and oxLDL uptake in the hypoxic environment 
of the advanced plaque. We observed that cells treated with DiL-oxLDL showed 
increased oxLDL uptake under hypoxia, which was abrogated after exposure of anti-
Lox-1 antibody. On the other hand, cells treated with DiL-acLDL showed just a slight 
increase in acLDL lipid uptake under hypoxia, but there was no difference in cells 
treated with a blocking Lox-1 antibody (data not shown). These observations suggest 
that Lox-1 contributes to the overall lipid content and particularly to the increased 
oxLDL uptake under hypoxia.  
 
Our in vivo results show the presence of TNFα and an increased expression of 
Lox-1 in the inner core of human advanced coronary plaques where the highest 
hypoxic microenvironment is expected. Our in vitro data in RAW264.7 cells show that 
HIF-1α was playing a role in Lox-1 upregulation under hypoxia, and that the blockade 
of this receptor reduced the hypoxic induction of lipid content and oxLDL uptake 
under low oxygen concentrations, highlighting its role in advanced atherogenesis. 
Furthermore, bioinformatic analysis showed the presence of putative hypoxia 
responsive elements (HREs) in both Lox-1 and SRA promoters at positions -114 and 
-578 respectively. However further studies are still required to verify the involvement 
of HIF in the regulation of Lox-1 and SRA under hypoxia. 
Macrophages obtained from human atherosclerotic plaques contain mainly 
cholesterol esters and high amounts of triglycerides. Some reverse cholesterol transport 
proteins have been reported, including our own work, to be induced in hypoxia. In our 
screening for differential gene expression involved in oxygen regulated cholesterol 
transport we observed that mRNA levels from reverse cholesterol transporters such as 
ABCA1 and ABCG1 were induced under hypoxia. Ugocsai and coworkers demonstrated 
that HIF-1α binds to the HRE of the ABCA1 promoter increasing ABCA1 activity and 
expression. They showed that exposure of human primary macrophages to hypoxia or to 
constitutively active HIF-1α increased ABCA1 expression. Furthermore, they also 
showed in vivo that in macrophages prepared from human atherosclerotic lesions 
ABCA1 levels showed a strong correlation with HIF-1β expression. This in vivo 
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regulatory mechanism was confirmed in human pre-eclamptic placentas, a clinical 
condition which also presents hypoxia [15]. Moreover, as discussed above, the 
scavenger receptor CD36 was affected also under hypoxic conditions.  
On the other hand, as mentioned bofere, FAS has been also demonstrated to be 
upregulated under hypoxic environments, as well as SREBP, which is the main regulator 
of the FAS gene [7]. Moreover, Li and coworkers showed that chronic intermittent 
hypoxia up regulates genes for lipid biosynthesis in obese mice. They observed the 
increase in multiple genes controlling 1) cholesterol and fatty acid biosynthesis (malic 
enzyme and acetyl coenzyme A (CoA) synthetase), 2) fatty acid biosynthesis (acetyl-
CoA carboxylase and stearoyl-CoA desaturases 1 and 2); and 3) triglyceride and 
phospholipid biosynthesis (mitochondrial glycerol-3-phosphate acyltransferase). 
Furthermore, they demonstrated that majority of overexpressed genes were 
transcriptionally regulated by SREBP, a master regulator of lipogenesis [3].  
Hypoxic environments present at the atherosclerotic lesion may be of importance 
for the vascular inflammatory processes as well. Using in vitro systems, it has been 
reported that HIF-1α activates NF-kB [16] and that  NF-κB controls HIF-1α transcription 
[17]. Rius and coworkers showed in mice lacking IKK-β, that NF-κB is a major 
transcriptional activator of HIF-1α and that basal NF-κB activity is required for HIF-1α 
protein accumulation under hypoxia. The authors performed their experiments in 
cultured cells and in the liver and brain of hypoxic animals. IKK-β deficiency results in 
defective induction of HIF-1α target genes including vascular endothelial growth factor. 
IKK-β is also essential for HIF-1α accumulation in macrophages experiencing a bacterial 
infection. Hence, this group links IKK-β as an important contributor to the hypoxic 
response, linking it to both innate immunity and inflammation [18]. Hypoxia induces the 
expression of a variety of proinflammatory cytokines, such as 15-lipoxygenase-2, 
eicosanoids, and TNFα [19]. Cytokines induce inflammatory responses including the 
increased production of lipid droplets [20]. Furthermore, activation of LXR stimulates 
production of TNFα [21], and hypoxia has been shown to upregulate LXR [22].  
Cholesterol rather than triglycerides are the most atherogenic lipids accumulated 
in foam cells [22]. However, in atherosclerotic lesions, the content of triglycerides is 
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higher in the musculo-elastic layer and even more in the elastic hyperplastic layer of the 
intima in comparison to normal aorta, indicating that the increases in triglyceride level 
also contribute to the pathogenesis of atherosclerosis [23].  
 
Many studies have shown that VLDL particles contribute directly to the 
intracellular and extracellular accumulation of lipids in atherosclerotic lesions [24].  Low 
oxygen conditions upregulate VLDL receptors on macrophages [25; 26], and increased 
levels of VLDL receptors are expressed by plaque macrophages in vivo [26].  These 
results suggest that hypoxic conditions may further enhance as well the VLDL-
associated accumulation of triglyceride in advanced atherosclerotic plaques.  
 
The effect of hypoxia on macrophages showed in this work could play a role in 
other contexts than atherosclerotic lesions. Tissue and cellular hypoxia is suggested to 
be of importance in various diseased and inflamed situations such as bacterial infections 
and wounds, tumors and diabetes. Situations where macrophages are present and 
accumulate under these circumstances activating gene expression after both, 
inflammatory and hypoxic stimuli. It is observed that more macrophages are found in 
ischemic hearts than in control hearts [27]. Moreover, there is an increased formation of 
lipid droplets and a predominant accumulation of triglycerides in hypoxic human hearts 
compared with controls [28]. 
 
The clinical trials for modulating scavenger receptor function have not been fully 
successful so far [29]. Since more than a decade ago, adenoviral approaches 
succeeded to modulate SRA gene expression in vivo [30] however the efficacy was not 
seen in a long-term basis [29].   
The Lox-1 scavenger receptor, as above mentioned, is involved in both early 
and late atherogenesis. Monitoring and targeting the membrane-bound receptor Lox-
1 in vascular tissues or in body fluids could give the opportunity to explore better 
treatments for vascular and pro-inflammatory diseases like atherosclerosis.  
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Reports on the impact of available pharmacological therapies on Lox-1 
expression in patients are still limited. Morawietz and coworkers demonstrated 
reduced Lox-1 expression in internal mammary arteries in patients receiving ACE 
inhibitors [31]. Moreover, clinical trials for endothelial protection, blockage of 
angiotensin I and statin receptor blockers improved anti-atherosclerotic endothelial 
expression quotient (which included mRNA expression of vasoprotective genes 
eNOS and CNP, divided by expression of proatherosclerotic genes Lox-1 and 
gp91phox) and endothelial function. However, Lox-1 expression itself was not 
significantly regulated by any medication [32].  Thus, antihypertensive and lipid-
lowering drugs currently available may not be sufficient to reduce Lox-1 expression 
and atherosclerosis in a clinically relevant manner. Even if Lox-1 blocking antibodies 
have been shown to preserve endothelial function in response to oxLDL in the current 
study, their application in clinical settings is limited. Further studies towards inhibition 
of Lox-1 might be an interesting and novel therapeutic strategy in the treatment of 
atherosclerosis and its clinical implications. 
Taking together, I suggest that endogenous content and uptake of lipids overrides 
the efflux of cholesterol by ABC transporters under hypoxic conditions.  Possibly the 
increased expression of Lox-1 during foam cell formation together with the increased 
hypoxic signaling in the atherosclerotic lesion may contribute to increases in the levels of 
cholesterol and triglycerides in macrophages leading to atherogenesis.   
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August 2009. Poster Presentation.  
urich Center for Integrative Human
urich Center for Integrative Human
urich Center for Integrative Human
Swiss Physiological Society Annua
xia Net Congress. Learning
• Z  Physiology Symposium Meeting. Zürich, Switzerland 
August 2010. Poster Presentation.  
• Z  Physiology Symposium Meeting. Zürich, Switzerland 
August 2011. Poster Presentation.  
• l Meeting. Fribourg, Switzerland. Oral presentation. 
September 2010.  
• Hypo  from Hypoxia Signaling. Bilbao, Spain.  Oral 
presentation. April, 2012. 
MEMBERSHIPS TO SOCIETIES: 
Swiss Physiological Society. 
European Atherosclerosis Society. 
PUBLICATIONS: 
Sophia J.A. Wuest, Margot Crucet, Claudio Gemperle, Angelika Weber, Martin Hersberger 
Expression of 12/15-lipoxygenases in human primary macrophages. Atherosclerosis. July, 
2012. In press. 
Margot Crucet, Sophia Wuest, Patrick Spielmann, Arnold von Eckardstein, Thomas F. 
Lüscher, Roland H. Wenger, and Christian M. Matter. Differential expression of hypoxia-
regulated scavenger receptors modulate lipid uptake in macrophages. (Manuscript in 
preparation). 
LABORATORY TECHNIQUES: 
Cellular Biology:  Primary cell culture (human monocytes) , RAW264.7 macrophages, Hepa1, 
Hep3B, HepG2, U2937, Hek293T, U2OS, THP1, Hela, MCF7.  Foam cell assays with Oil Red O 
technique,  Flow Cytometry,  Fluorescent microscopy, Transient transfections (Amaxa 
electroporation, Lipofectamine, Metafectane, PEI, etc), stable transfections,  lentiviral production 
and infection (shRNA). 
Molecular  Biology:  RNA and genomic DNA extraction, PCR,  qRT-PCR, Western blotting,  
Cloning, Viral Complementation Assays, Promoter studies using reporter Luciferase Assays, 
Immunoprecipitation. 
In vivo: Handling of mice, hypertensive rats (SHRs) and Wistar–Kyoto (WKY) rats. 
Histology: immunohisto/cytochemistry, immunofluorescence, confocal imaging . 
Bioinformatics: USCS Genome Bioinformatics, Minimotif Miner, Clone manager, Jaspar 
database. 
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